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Abstract 
 
The interest in the design of portable and wearable medical devices is related to both the relevant 
clinical and social benefits for patients and the potential economic savings for national health services. 
Biomedical technologies are improving at a very fast rate and represent an extraordinary means to 
develop innovative portable and wearable devices which can help people live in a prosperous way, in 
particular reducing sorrow in case of disease. This leads to a widespread effort to develop devices 
which can execute at home therapies that are usually performed in hospitals.  
This thesis presents a new wearable and portable device for extracorporeal blood ultrafiltration, 
named WUF (Wearable UltraFiltration device), able to remove excess fluids from fluid overload 
patients with chronic kidney disease and/or congestive heart failure.  
The design requirements that a modern wearable device for extracorporeal ultrafiltration must meet 
have been identified thanks to a thorough literature review on previous similar proposals followed by 
an extensive risk analysis.  
The design of the WUF prototype has faced several difficulties, ranging from the identification or 
conceivement of safe and reliable components to the design of a compact and neat layout. For most 
components it was possible to identify commercial (off-the-shelf) products meeting the requirements, 
nonetheless for some others, specific investigations, studies and developments were needed and led 
to the design of customized solutions or the formulation of original approaches.  
The design of an effective, efficient, safe and reliable control architecture, based on two 
microcontrollers and one microcomputer, the implementation of the control logic and of a graphical 
user interface have been carried out too being essential features of such a mechatronic device.  
A backpack/trolley design has been chosen as the layout for the device, since such a solution 
guarantees the best tradeoff between miniaturization and ergonomics. The design introduces an 
original positioning of the vast majority of components in three independent planar panels: one for 
disposable components, one for non-disposable devices and one for electronic boards and controllers. 
This arrangement of components can drastically simplify and speed up the in-hospital operations 
needed before and after a therapy with the WUF 
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1. Introduction 
Fluid overload is a clinical condition in which the accumulation of water in the body cannot be 
excreted. One of the main consequences of fluid overload is electrolytes imbalance, in particular of 
sodium (whose normal level is diluted), which possibly determines digestive problems, behavioral 
changes, brain damage, seizures and sometimes even coma. Since the brain is the most susceptible 
organ to fluid overload, one of the first symptoms coming from an excess of water is a change in 
behavior: patients may become confused or inattentive, shouting and even being delirious. Other 
symptoms may be muscle cramps and twitching, paralysis of part of the body, rapid breathing, sudden 
weight gain, nausea and vomiting. Blood pressure may be higher than normal, but sometimes it can 
be a hidden consequence, although the degree of water intoxication is serious. In the worst case, fluid 
overload condition can cause acidosis (abnormal high acid content in blood and body tissues), anemia, 
cyanosis (sharp drop of blood oxygen levels), hemorrhage, and shock [1]. 
When the clinical condition of accumulation of water in the body is chronic, the causes are related to 
organ diseases. In particular, the organs that lead to fluid overload are kidneys and heart.  
 
1.1 The kidneys and kidney diseases 
The kidneys are a fundamental part of the urinary tract and perform crucial functions for the entire 
body. In particular, their functions can be summarized as: 
• regulating the water fluid levels; 
• regulating the electrolytes balance;  
• blood filtering and extraction of waste solutes and other substances (e.g. drugs); 
• maintenance of an important sector of the regulation of acid-base balance; 
• release of systemic hormones for regulating blood PH and blood pressure; 
• secretion of hormones such erythropoietin (fundamental for the production and maturation 
of red blood cells), renin and prostaglandin (for the regulation of arterial pressure)  
• production of an active form of vitamin D that promotes strong, healthy bones; 
• metabolism of carbohydrates. 
 
In case of damage, the different tasks and functions of the kidney involve also the functionality of all 
the other organs of the patient.  
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The two symmetrical kidneys are in a retroperitoneal position, between the eleventh chest vertebrae 
and the third lumbar vertebrae. In an adult person, their average weight is 150 g, with dimensions of 
12 cm × 6.5 cm × 3 cm. Each kidney is irrorated by the renal artery, that is a side branch of the 
abdominal aorta. It is divided into smaller branches that, becoming smaller and smaller, reach the 
capillarization and form a vascular cluster, the so-called renal glomeruli, constituting the kidney 
filtration system (Figure 1).  
 
Figure 1. Macroscopic structure of the kidney 
 
The nephron is the renal functional unit. For each kidney, there are one million nephrons and their 
main function is the urine production. Each nephron is basically constituted of two main components: 
the renal corpuscle and the renal tubule (Figure 2). 
 
Figure 2. Structure of the nephron 
 
The renal corpuscle, that consists of glomerulus wrapped in a structure named Bowman’s capsule, is 
the main responsible for the so-called ultrafiltration of the plasma: the blood entering into glomeruli 
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is filtered and the retained one (primary urine or glomerular filtrate) passes through renal tubules, 
where water and products are secreted or re-adsorbed based on the needs of the organism. At this 
point the urine is formed and it will be made pass to the bladder through the ureter [2]. 
Kidneys filter almost 200 l of water every day; of these, only 2 l are excreted as urine, the remaining 
are re-adsorbed from the organism, recovering all the useful substances that must not be released.       
 
1.1.1 Kidney Function 
The main parameter used to measure the kidney function is the glomerular filtration rate (GFR), that 
defines how much blood passes through the glomeruli per unit of time.  
In the clinical practice, the creatinine, a specific metabolism product that is almost completely 
removed by corporeal fluids through glomerular filtration, is used to estimate the GFR. 
As first approximation, the GFR can be calculated as: 
 
𝐺𝐹𝑅 =
𝐶𝑢,𝐶𝑟  ×  𝑉
𝐶𝑝,𝐶𝑟
 
 
where Cu,Cr is the creatine concentration in urine, Cp,Cr is the creatinine concentration in plasma and 
V is the urinary flow. 
Other formulas can be used for the estimation of the GFR: CockcroftGault and MDRD (Modification 
of Diet in Renal Disease) are two examples. These formulas are based on sex, age, race, blood 
creatinine levels and other biochemical parameters [3, 4]. 
In a healthy person, a normal GFR value is about 125 ml/min. This parameter is very useful for the 
detection and classification of any renal dysfunction or disease.   
 
1.1.2 Renal diseases 
Depending on the anatomic part of the kidney that is insulted, renal pathologies can be classified in: 
• Glomerular 
• Tubular 
• Interstitial  
• Vascular 
• mixed   
6 
 
Serious diseases, which can potentially compromise even in an irreversible way the kidney functions, 
can be basically categorized in: 
• Acute kidney injury, where the loss of functionality is sudden, but there are high 
possibilities of recovery and regression (potential causes may be traumas, accidents or 
taking toxic drugs); 
• Chronic kidney Disease, where the progressive reduction of the functionality of nephrons is 
irreversible. 
The majority of kidney diseases occur when the nephrons are insulted. If the nephrons lose their 
capacity to filter fluids and solutes, fluid and toxins levels can accumulate in the organism, leading 
to severe clinical consequences.  
The chronic kidney disease derives from the loss of a big number of nephrons. Usually, no serious 
clinical symptoms appear until the number of working nephrons falls below 70-75%. Indeed, 
electrolytes plasma concentration can still be maintained in a normal range and the volume of body 
fluid can remain normal until the number of working nephrons falls below 20-25%. There are 
different stages to indicate the severity of the disease according to the value of GFR. They are 
described in the following Table 1, according to the K-DOQI (Kidney Disease Outcome Quality 
Initiative) guidelines [5]: 
Stage Description GFR 
(ml/(min·1.73m2)) 
1 
Normal kidney function but urine findings or structural 
abnormalities or genetic trait point to kidney disease 
> 90 
2 
Mildly reduced kidney function, and other findings (as for 
stage 1) point to kidney disease 
60-89 
3 Moderately reduced kidney function 30-59 
4 Severely reduced kidney function 15-29 
5 Very severe, or end stage kidney failure  < 15 
Table 1. K-DOQI classification for chronic kidney disease (1.73 m2 refers to the standardized body surface area used to 
normalize for all variables for an average 70 kg man) 
  
In this case, the renal function slowly decreases over a relatively long period of time, from months to 
years, and the rate of progression depends on the disease that caused the kidney failure, although a 
large individual variability is observed. 
The major causes of chronic kidney disease are: 
• Diabetes and hypertension, responsible for more than two-thirds of the cases; 
• Glomerulonephritis, causing inflammation and damage to glomeruli; 
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• Pyelonephritis and interstitial nephritis, involving the kidneys in their tubular and interstitial 
components. They can be caused by recurrent infections, drug abuse or chronic illness or 
obstructive urinary tract pathologies; 
• Hereditary diseases (e.g. polycystic kidney disease). 
 
When the kidney failure reaches advanced stages (stage 4 and 5), solutes and fluids accumulate in the 
organism, and the fluid overload condition is reached. In these cases, the condition of fluid overload 
becomes important: patients with chronic kidney disease require to consume specific food and must 
drink small amounts of water and a substitution therapy, represented by dialysis or transplantation, is 
necessary. 
 
Worldwide, renal dysfunction-related pathologies are one of the most important causes of death and 
invalidity. In USA, in 2015, it was estimated that more than 660000 people have been treated for 
kidney failure [6]. In Europe, almost 700000 people [7] have completely or partially lost some of the 
primary kidney functions (prevalent risk factors were aging, diabetes and obesity), determining a high 
risks condition and the need for renal replacement therapies (such as extracorporeal hemodialysis, 
peritoneal dialysis or transplantation). Furthermore, the increasing incidence of chronic kidney 
diseases all over the world represents an issue in the field of the health economy: hemodialysis 
treatment costs an average of 89.000 $ per patient annually in the United States [6] and an average of 
43.800 € per patient in Italy [8]. 
 
1.2 Heart disease 
Although the condition of fluid overload is mainly caused by kidney failures, even heart diseases can 
determine an accumulation of fluids in the body. Normal pressure within blood vessels is partly 
maintained by the pumping force of the heart. However, if the heart starts to fail, changes in blood 
pressure are observed, often resulting in serious water retention. Typically, in such condition, legs, 
feet, and ankles will swell. Fluid will also build up in the lungs, giving to the patient a long-term 
cough and/or difficulty breathing and often leading to edemas. Heart failure with this kind of fluid 
buildup is called congestive heart failure.  
Depending on the part of the heart that is affected by the failure, the position of the edema occurs in 
the body. If the abnormality is in the left ventricle, it means that it cannot pump blood out to the body 
as fast as it returns from the lungs. Since blood cannot get back to the heart, it begins to back up in 
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the blood vessels of the lungs. Consequently, part of the fluid in the blood is forced into the breathing 
space of the lungs, causing pulmonary edema. Symptoms of pulmonary edema can be shortness of 
breath and tiredness, since oxygen and nutrients circulating in the blood are not enough to supply 
body's tissues. Abnormalities of the heart structure and rhythm can also be responsible for left 
ventricular congestive heart failure.  
If the abnormality is in right-sided heart failure, it cannot pump blood to the lungs as fast as it returns 
from the body through the veins. As a consequence, blood engorges the right side of the heart and the 
veins. Fluids in the veins are forced out into the tissues, causing swelling. Congestive heart failure of 
the right ventricle is often caused by abnormalities of the heart valves and lung disorders. 
When the heart cannot pump enough blood, it is forced to become larger in order to supply the missing 
oxygen and fluids. By becoming enlarged (hypertrophic), the ventricles can contract more strongly 
and pump more blood. In this case, the heart chamber becomes larger and the muscle in the heart wall 
becomes thicker. The kidneys try to compensate for the failing heart by retaining more salt and water 
to increase the volume of blood. This extra fluid also can cause edema. Kidneys often become weaker 
if these circumstances are present, leading to a disease that is called cardio-renal syndrome [9, 10]. 
According to estimations from the European Heart Failure Association, 26 million people have heart 
failure worldwide and 3.6 million people are newly diagnosed with heart failure every year in Europe 
alone [11-13]. Similar data can be seen even in the United States. In accordance to the American 
Heart Association [14, 15], about 4.9 million Americans suffer from congestive heart failure. Sex is 
not a discriminating factor (50% are males and 50% are females). 0,1% of people over 65 years suffer 
from this condition. 
 
 
1.3 Therapies for fluid overload 
When the condition of fluid overload becomes severe, therapies for treating such disease must be 
applied. The treatment of fluid overload may depend on the clinical status of the patient, acuteness of 
the condition and underlying causes. Basically, treatment consists of: 
• Drugs 
o Diuretics to increase urination 
o Vasopressin receptor antagonists (to treat hyponatremia) 
• Extracorporeal therapy 
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Patients with chronic kidney disease have a renal functionality which is completely lost and, 
consequently, any diuretic results inefficient. On the contrary, congestive heart failure patients still 
having renal function can take diuretics.  
Renal replacement therapies aim to completely substitute the renal function, and consequently to re-
establish the correct fluid volume in the body, in patients affected by chronic kidney disease. Between 
them, three main treatments can be carried out: 
• Renal transplantation 
• Peritoneal dialysis therapy 
• Extracorporeal hemodialysis therapy 
The first option involves the transplantation of the kidney from a donor (even a living one) through a 
surgical intervention; this solution is considered the preferable option, since it allows to completely 
solve the insufficiency and potentially allows patients to return to normal everyday life. However, in 
order to perform a transplantation procedure, in addition to the need of a donor and therefore of the 
organ, it is also necessary that the donor and the patient are hystocompatible. If this is not verified, 
the patient's immune system will not recognize the transplanted kidney and will generate a strong 
response of the immunological barriers, eventually causing organ rejection and transplant failure. In 
order to avoid it, immunosuppressant drugs need to be administered to the transplanted patient.  
Peritoneal dialysis is a therapy that can be prescribed when the GFR is less than 10%. It exploits the 
peritoneal cavity, which is the membrane surrounding the organs’ walls of the abdomen and the 
abdominal organs, by which blood is internally filtered and purified. Inside this cavity, a specific 
dialysis solution is drained through a peritoneal catheter implanted with a minor surgical procedure. 
Consequently, the renal function is replaced by the peritoneum which then acts as a filter for solutes 
and excess fluid in the blood. The dialysis solution has to be periodically replaced with a virgin 
solution. Currently, two methods for draining the solution are used: the Continuous Ambulatory 
Peritoneal Dialysis (CAPD), which consists of exchanging 2-3 liters of dialysis solution for a duration 
of about 30 minutes, cyclically performed every 6-8 hours during the course of the day, or Automatic 
Peritoneal Dialysis (APD), which automatically regenerates the dialysis solution in a single operation 
of 8 to 10 hours overnight. One of the main disadvantages of this therapy is the risk of infection of 
the peritoneum, often due to the peritoneal catheter.  
The last renal replacement therapy is the extracorporeal hemodialysis. Usually, hemodialysis patients 
are treated in equipped hospitals, three times a week, for a period between 4 and 6 hours per session. 
The blood is drawn by a specific vascular access, made pass through an extracorporeal circuit, filtered 
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and purified by a specific medical device called hemodialyzer (or hemofilter), and then re-infused 
into the patient. The actuation and control of all processes are performed by specific machines. The 
term hemodialysis refers to different techniques that can be applied depending on the clinical aim to 
reach. If the clinical aim is to remove excess water from a patient, the specific technique to apply is 
called ultrafiltration.      
Congestive heart failure patients with no kidney disease may be treated with diuretic drugs. In order 
to reduce the overload volume, fluid overload patients are therapeutically treated with diuretics 
administered intravenously [16-18]. Although diuretics are mainly used for the treatment of acute 
decompensated heart failure, the use of extracorporeal ultrafiltration (UF) is becoming an alternative 
strategy for reducing volume overloads in these patients [18]. The chronic use of diuretics has been 
associated with negative neuro-hormonal effects [19] and, mostly, it might cause drug resistance [20]. 
Such diuretic resistance has been estimated to occur in 20% or more of patients with decompensated 
heart failure [21]. Furthermore, diuretic resistance is associated with poor prognosis and higher 
incidence of morbidity in fluid overload patients with heart failure [22]. For these reasons, 
extracorporeal ultrafiltration seems to have potential advantages as therapy for the treatment of fluid 
overload in congestive heart failure patients, including greater control over the rate and volume of 
fluid removal, greater net loss of sodium, and less neurohormonal activation [23, 24]. Current 
treatment guidelines state that ultrafiltration is a reasonable approach in patients with congestion that 
is not responding to medical therapy (class IIa, level of evidence B) [25]. 
 
1.3.1 Ultrafiltration Therapy 
Ultrafiltration therapy is an extracorporeal technique which allows a slow but continuous removal of 
excessive water from the blood in extracorporeal circulation. The patient’s clinical tolerance to fluid 
removal is the key issue to perform a successful extracorporeal ultrafiltration [26]. In order to achieve 
an adequate fluid removal and to maintain an acceptable hemodynamic stability in a patient, it is 
fundamental to accurately define the amount of fluid to be removed, to reach an optimization of the 
rate of fluid removal and to maintain the circulating blood volume [27]. If plasma water removal is 
too aggressive, blood volume may decrease in consequence of a too slow intravascular refilling, that 
is the rate of water movement from the interstitial space to the vascular space. If this happens, severe 
hemodynamic instability may occur. On the other hand, in the presence of a slow continuous 
ultrafiltration, an effective correction of the extracellular fluid volume takes place due to a progressive 
intravascular refilling from the interstitial spaces. 
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The extracorporeal blood ultrafiltration therapy is carried out through specific machines in hospital. 
In order to take out blood from a patient’s vascular circulation, a specific vascular access needs to be 
implanted. The most used vascular access for this type of therapy is a dual lumen catheter, which 
allows to take out and re-infuse blood to the patient punching the vessel only once. Typically, the 
catheter is positioned in the jugular of femoral vein, which is a large-caliber blood vessel, in order to 
guarantee high blood flows flowing inside the extracorporeal circuit. Another possibility of vascular 
access is a clinical connection of an arteriovenous shunt, called arteriovenous fistula. In 
extracorporeal therapies, the blood flow is typically 100-150 ml/min in adults. Blood, from the 
catheter, circulates into a disposable extracorporeal circuit that shall be adapted with the interface of 
the so-called “hardware” of the ultrafiltration machine [28, 29].  
Since blood exits from a vein and returns to the same vein, an external pump generating a pressure 
gradient is necessary in order to perform extracorporeal circulation. Modern ultrafiltration machines 
are equipped with hemo-compatible peristaltic pumps and safety mechanical components that must 
guarantee safety of patients during the process. The core of the filtering process takes place inside a 
disposable component called hemodialyzer or hemofilter (Figure 3): it is a device constituted of a 
semipermeable membrane that allows the filtration of plasma water and suspended particulates 
(among which electrolytes like sodium and potassium) and the retention of components that do not 
have to be removed from patients, like many proteins and red blood cells.  
 
Figure 3. Typical design and components of a hemofilter for blood ultrafiltration 
 
The membrane is made by several (a number between 2500 and 10000) hemo-compatible polymeric 
hollow fibers, porous on the surface, through which blood flows. In the space between fibers, the 
removed fluid (ultrafiltrate) is collected (Figure 4) and then removed. The physical phenomenon of 
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filtration is called ultrafiltration, because pores have an average diameter smaller than 100 nm. 
Usually, the cut-off value of the membrane is expressed in Daltons (Da), indicating the molecular 
weight of the smallest solute that statistically can cross the membrane.  
 
Figure 4. Principle of blood ultrafiltration 
The driving force promoting the separation is the hydrostatic pressure gradient across the membrane: 
a negative pressure is applied in the ultrafiltrate compartment of the filter through a pump (the 
ultrafiltration pump) in order to generate a positive transmembrane pressure (TMP). In details, the 
TMP can be expressed by the following formula: 
𝑇𝑀𝑃 (𝑥) =  𝑃𝑏(𝑥) − 𝑃𝑈𝐹(𝑥) −  𝛱(𝑥) 
where Pb(x) is the pressure in the blood compartment, Pd(x) is the pressure in the ultrafiltrate 
compartment and Π(x) is the oncotic pressure exerted by blood proteins, along the axial coordinate x 
of the length (L) of the filter. In order to have movement of plasma water from blood compartment 
to ultrafiltrate compartment, (∫ 𝑇𝑀𝑃 𝑑𝑥
𝐿
0
) has to be positive.  
Together with water, even solutes are removed during the ultrafiltration process. The movement of 
solute is made possible by physical phenomena of convection and absorption.  
Convection is bulk-flow of solute across the semi-permeable membrane together with a solvent in a 
manner that is dependent on transmembrane pressure and membrane characteristics. The convective 
flux of a solute depends on the ultrafiltration flow set, total membrane surface area, solute 
concentration in plasma and solute sieving coefficient, that indicates the statistical probability of that 
specific solute to cross the membrane. 
Adsorption is a process in which molecules dissolved in plasma or blood (in particular peptides and 
proteins) bind to the membrane structure. The characteristics that influence molecule-membrane 
interaction are typical for each molecule (i.e., dimension, charge, and structure) and for each 
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particular membrane (i.e., porosity, composition, hydrophobicity, surface potential). The adsorption, 
during any extracorporeal treatment, has advantages and disadvantages. Indeed, if on the one hand it 
allows direct clearance of toxic solutes, giving an important contribution to the total removal of 
solutes, on the other hand it can be considered even an undesirable phenomenon since big solutes, 
adhering to the walls of the membrane, may increase the resistance to the passage of other solutes 
and fluids, reducing the hydraulic permeability of the membrane and reducing the filter efficiency.  
 
1.3.2 Machines for ultrafiltration therapy 
Ultrafiltration machine includes the non-disposable and disposable (i.e. single use) components of 
the circuit through which blood flows. The main non-disposable components of a standard 
ultrafiltration machine, based on current technology and characteristics [29-31], are depicted in 
Figure 5 on a schematic sketch of machine. 
 
Figure 5. Schematic representation of ultrafiltration machine 
 
The main components are: 
1  Screen: the monitor through which the user interacts with the machine. 
2 Alarm light and sound indicators: visual and auditory alarms must be clear and comprehensive.  
3-4-5-6 Pressure sensors: monitor pressures in the extracorporeal disposable circuit 
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7 Blood pump: pump that controls the blood flow rate through the extracorporeal circuit. 
8 Filter holder: holds the filter or the entire filter-tubing kit on the machine. 
9 Bubble detector: transducer that detects the presence of air in the blood out-flow line. 
10 Safety out-flow electroclamp: a mechanism that produces occlusion of the blood out-flow line. 
11 Blood leak detector (BLD): placed along the effluent line, it identifies unwanted blood leaks 
from the blood compartment of the filter. 
12 Effluent/ultrafiltrate pump: pump that controls the rate of total fluid removal from the filter. 
13 Fluid control system: allows direct monitoring of the fluid balance related to fluids exchanged 
by the ultrafiltration machine during the treatment. It is usually a gravimetric system (using one 
or more load cells)  
Furthermore, it is necessary to include in this category also all the electronic components that 
implement the machine control logic and functions needed for the correct execution of the therapy in 
addition to the management of the machine, failures and emergencies. A list of elements that are part 
of the control system includes: 
• Microprocessors  
• ADC and DAC converters 
• Electric motors and related transducers 
• Visual and light indicators (including those in the above point 2) 
• Power supply systems and voltage transformers 
• Ports for I/O interfaces and data exchange, data bus 
• Batteries (if needed) 
Disposables (i.e. the single-use components of the extracorporeal circuit) are specific for every 
machine and are usually designed for specific therapies, such us ultrafiltration. Following the scheme 
of Figure 5, the main disposables, components and color codes that should mark each tubing line in 
ultrafiltration modality [29] are: 
• Blood access or in-flow line (red), which contains:  
o Segment connecting the patient’s vascular access to the filter 
o Segment for pressure measurement upstream blood pump 
o Pump segment line 
o Segment for pressure measurement downstream blood pump 
• Blood out-flow line (dark blue), which contains 
o Segment connecting the filter to the patient’s vascular access 
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o Segment for pressure measurement after the filter 
o Blood out-flow air removal chamber: allows removal of light air bubbles before 
blood returns to the patient 
• Ultrafiltrate line (yellow) 
o Segment that allows the flow of waste fluids from the filter 
o Pump segment line 
o Segment for pressure measurement in the ultrafiltrate line. 
Some of the most recent and representative hardware machines available in the market are shown in 
Figure 6, and are manufactured by Fresenius Medical Care (1), Baxter (2), Bellco (3), BBraun (4), 
Asahi Kasey Medical (5).  
 
Figure 6. Examples of ultrafiltration machines worldwide used (1 Multifltrate Pro (Fresenius Medical Care), 2 
Prismaflex (Baxter), 3 Amplya (Bellco), 4 Omni (BBraun), 5 (Kibou (Asahi Kasey Medical)) 
The management and set-up of these machines are not easy: consequently, a specialized and trained 
nursing and technical staff has to be present in all medical facilities that perform this kind of 
treatments. 
Although ultrafiltration machines are efficient for treatments applied in hospitals, they suffer from 
several drawbacks. Usually, these devices are cumbersome, heavy and must be hooked to electrical 
outlets. Since fluid overload patients undergoing ultrafiltration therapy must remain connected to 
these devices for several hours, their ability to perform normal everyday activities is severely limited. 
In addition, typical ultrafiltration treatments are geared for fast removal of excess fluid. However, the 
removal of water is only temporary and the excess fluid usually reaccumulates in the patient's body 
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quickly. The re-accumulation of fluid is harmful to the patients, as the kidneys are further injured by 
the progress of congestive heart failure and the side effects of the diuretic drugs used to treat the heart.  
For hemodialysis patients, a further problem with ultrafiltration machines is that repeated 
reconnection to these devices requires accessing blood flow by puncturing fistula (if the arteriovenous 
fistula is used). These shunts only last for limited periods of time and are subject to infection, clotting 
and other complications that result in numerous hospitalizations and repeated surgical interventions. 
If the used vascular access is a catheter, similar problems also exist. 
In view of the above disadvantages and in such a context, there is a substantial need for a wearable 
ultrafiltration device (WUF) that provides continual, steady and smooth removal of excess fluid from 
the body. 
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2. Rationale and aim of the project 
 
Biomedical technologies are improving at a very fast rate and represent an extraordinary means to 
help people to live in a prosperous way, reducing sorrow even in case of a disease. Additionally, in a 
society where everything is becoming increasingly mobile, it is not surprising that medical devices 
traditionally used in hospitals are evolving to become more portable and even wearable, giving the 
possibility to use them in the home healthcare market so as to reduce patients’ hospitalization. 
Estimations say that the homecare medical equipment market could be worth billions of dollars by 
2022 [32]. In response, medical device manufacturers are designing smaller practical solutions. By 
the same token, smaller components such as sensors, are growing in demand for applications in 
portable and wearable devices. However, functionality, reliability and mostly safety cannot be 
sacrificed for smaller form factors. For most manufacturers, budgets are not unlimited, and 
additionally, national healthcare systems are always seeking for cost savings. This means that low-
cost components are the ideal solution when they are proved to be reliable. The advantage to portable 
medical devices is that they extend care from the doctor’s office into patients’ home so diseases that 
are caught earlier are more easily treated. Finally, wearable systems can be broadly defined as mobile 
devices that can be unobtrusively embedded in the user’s outfit as part of the clothing or an accessory. 
Based on these considerations, the aim of this PhD project is to develop a mechatronic, miniaturized, 
portable and wearable device for delivering a complete blood ultrafiltration therapy. Such a treatment 
is indicated for the slow and continuous (24 hours a day) removal of fluids from blood in patients 
suffering from a condition of fluid overload. 
Generally, as previously mentioned, ultrafiltration machines used for treating fluid overload in 
patients with chronic kidney disease or congestive heart failure are very bulky and difficult to move, 
forcing patients to be hospitalized and requiring continuous monitoring by hospital personnel. Several 
and long hospitalizations in departments such as nephrology or cardiology may possibly lead to an 
inadequate care of the numerous pathological events that may occur in the hospital, and obviously, 
force patients not to enjoy a normal life style together with the chronic pathology.  
Worldwide, the scientific community is trying to overcome these issues by providing innovative 
technological solutions for the extracorporeal ultrafiltration therapy. One of the most exciting is the 
design of portable and wearable devices for continuous ultrafiltration, possibly monitored remotely 
and autonomously. Such a solution may lead to several benefits depending on the target class of 
patients which is considered: 
• Patients with chronic kidney disease in extracorporeal renal replacement therapy; 
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• Patients with congestive heart failure. 
In the present project, the use and the application of a WUF for patients with chronic kidney disease 
in extracorporeal renal replacement therapy needs to be intended as an inter-dialysis sessions therapy, 
meaning that it is performed in days between two hospitalized dialysis sessions. Consequently, 
ultrafiltration therapy with a wearable and portable device will be supplementary to the standard 
dialysis. For these patients, the benefits can be defined as: 
• Clinical-therapeutic advantages and aspects 
o Inter-dialytic removal of water (although partial) may lead to a reduction of the 
incidence of cardiovascular complications (decrease of cardiac workload); 
o Reduction of the number of episodes of acute pulmonary edema;   
o Reduction of blood pressure levels, between two dialysis sessions, in hypertensive 
patients, caused by fluid overload;      
o Reduction in use of diuretics drugs for patients with residual renal function; 
o Reduction of hypotensive episodes during the dialysis session;   
o Reduction of the frequency of dialysis sessions;      
o Time reduction of a single dialysis session;      
o Therapy and device personalization;  
o Improvement of the clinical condition of fluid overload with direct impact on other 
systems like cardiovascular and gastrointestinal ones;     
o An extra-dialysis fluid removal lead to a solutes blood purification (even if small), as 
a consequence of a higher fluid assumption (i.e. drinking) by patients.  
  
• Social advantages and aspects 
o Opportunity to have more freedom for patients in food and drink intake; 
o Improvement of the quality of life at the expanse of an additional therapy for patients; 
o Possibility to perform daily activities during therapy by patients. 
 
• Economic advantages and aspects 
o Cost reduction as a consequence of shorter dialysis sessions; 
o Cost reduction as a consequence of a reduced assumption of drugs (diuretics, EPO, 
beta blockers); 
o Cost reduction as a consequence of a reduced hospitalization in Outpatient Nephrology 
Units, Inpatient Nephrology Units, Intensive Care Units 
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Furthermore, the development of such a prototype for chronic kidney disease patients can be a useful 
exercise towards a future dialysis portable device. 
For congestive heart failure patients, the ultrafiltration therapy should be considered as continuous, 
meaning that it can be applied continuously for 24 hours/day. Consequently, the ultrafiltration therapy 
with wearable and portable device would be alternative to the one performed with standard machines 
in hospital or to diuretic therapies. The main benefits for these patients would be: 
• Clinical-therapeutic advantages and aspects 
o Reduction of clinical complications related to chronic kidney diseases (cardio-renal 
syndromes);      
o Reduction and/or removal of assumption of diuretics drugs ;    
o Reduction of the risk of worsening of the heart disease;     
o Recovery and/or improvement of cardiac performance;     
o Reduction of the episodes of acute pulmonary edema;     
o Therapy and device personalization. 
 
• Social advantages and aspects 
o Opportunity to have more freedom for the patient in food and drink intake; 
o Possibility to perform daily activities during the therapy; 
o For patients who perform hospitalized therapy, ease of movement between 
departments for other clinical investigations. 
 
Thus, summarizing, a wearable ultrafiltration device would have the potential to implement a not 
impetuous blood ultrafiltration therapy out of hospital over an extended period of time, making this 
process closer to natural body water removing, reducing total therapy costs and improving patients’ 
quality of life.  
The PhD activity has been carried out within the framework of a multidisciplinary project “RAP” 
funded by Fondazione Cariverona and which has involved engineers of the Department of 
Management and Engineering (DTG - Dipartimento di Tecnica e Gestione dei Sistemi Industriali) of 
the University of Padova and the medical staff of both the department of Nephrology, Dialysis and 
Transplantation and the International Renal Research Institute of Vicenza (IRRIV) of the San Bortolo 
Hospital of Vicenza. The PhD grant has been funded by the project RAP: therefore the PhD and the 
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project RAP activities have been carried out in a very synergistic way throughout all the 3 years. This 
thesis only presents the activities the PhD project has been focused on.  
The remaining of thesis is organized as follows. After a literature review, specifically focused on 
wearable devices performing therapies similar to ultrafiltration and on the definition of 
clinical/technical limitations and potential breakthroughs for each of them (Section 3), an extensive 
risk analysis has been performed aiming to set the design requirements first in clinical terms and then 
in technological ones (Section 4). Such an analysis has allowed identifying the essential components 
of the wearable system, which are discussed in detail in Section 5. For some components commercial 
(off-the-shelf) products were available, for other ones specific investigations, studies and 
developments were needed: they are therefore named “critical components”. Most of such 
investigations have been carried out in hospital, using biological fluids (e.g. blood) and simulating a 
real environment for the application. Then, in Section 6, the design of the control architecture, the 
implementation of the control logic and of graphical user interface are presented. Finally, in Section 
7, after having chosen every single component of the device, the investigation of the most effective 
device layout is discussed, the objective is finding the best tradeoff between miniaturization and 
ergonomics. The prototype of the device is finally presented in the Section 8, while concluding 
remarks are given in Section 9.        
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3. Literature review 
 
Previous proposals of wearable/portable biomedical devices for ultrafiltration or similar therapies 
(such hemodialysis, hemoperfusion or peritoneal dialysis) have been analyzed to identify 
technological breakthroughs and limitations for each of them. 
Several prototypes with a similar therapeutic target have been developed to date [33] (Table 2). 
Although many of them have contributed to a scientific progress in this field, technological limitations 
still limit the potential clinical application and the industrialization of such devices. In particular, the 
main technological issues are related to the requirement of combining high levels of safety for patients 
together with miniaturization of components and low energy consumption. 
 
 
 
Table 2. Previous prototypes and their chief characteristics developed or under development 
 
Apart from two devices (the WAK and WHF, whose components are basically the same), none of the 
devices listed in Table 2 is under clinical trial. There follows a description of the chief features of 
each of the devices in Table 2. 
 
WAK 
The first and probably the most known wearable and portable device for extracorporeal blood 
purification therapies developed so far is the Wearable Artificial Kidney (WAK). The device (Figure 
Name Year Therapy
Technological 
breakthrough 
Current status Chief limitations
The WAK 2007 Hemodialysis (HD) 
Pulsatile pump 
REDY cartridge
Clinical trial High weight, the bell is bulky
ViWAK  2007 Peritoneal dialysis (PD)
Remote control 
Double lumen PD catheter
Prototype PD is a less efficient therapy
AWAK  2008 Peritoneal dialysis (PD)
REDY cartridge
Protein regeneration
Before 
clinical trial
PD is a less efficient therapy
The WHF 2008 Ultrafiltration (HF) Pulsatile pump Clinical trial High weight, the bell is bulky
RAD (IAK) 2009 Hemo-Filtration Reinfusion (HFR)
Nanostructured hemofilter
Cell function
Under 
development
Water cannot be removed
iNephron 2010
Fractionated Plasma 
Separation Adsorption (FPSA) 
Nanostructured sorbents
ICT-integration
Prototype Conceptual prototype
WAKMAN 2011 Hemofiltration (HF) 
Pump-hemofilter unit
Remote control
Prototype Only pump-filter unit
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7) [34, 35], developed by Professor Gura and his group at the University of California, is a woven 
belt of a total weight of 2.3 kg, powered by two standard 9V batteries, that can be connected to the 
patient’s vascular access through a fistula or a central venous catheter. The therapy applied with this 
device is hemodialysis: a counter-current flowing of a specific solution of sterile water and 
electrolytes (the dialysate) is made pass through the space between fibers, generating a concentration 
gradient across the membrane and allowing blood toxins to be removed by diffusion. The blood pump 
is not a traditional roller pump, feature of standard hemodialysis machines, but it is a biventricular 
pump (so called shuttle-pump) consisting of a double channel pulsatile counter phase flow, one for 
blood and one for dialysate [36]. The two chambers containing the fluids are disposable. When the 
blood chamber is full, the dialysate one is empty and vice versa. This implies a pulsatile flow of both 
fluids and a pressure gradient generated across the membrane of the filter, resulting in a good 
clearance of solutes to be removed. The dialyzer surface is A= 0.2 m². The dialysate is partially 
regenerated by a system of REDY [37] absorbing cartridges (three cartridges in series containing 
urease, active carbon and chloride loaded zirconium oxide together with zirconium phosphate), that 
consequently reduces the total volume of water necessary to purify the blood to 375 ml. The excess 
water removed is regulated by a peristaltic ultrafiltration pump and, as in the conventional 
hemodialysis machines, the device provides for safety systems that stop the bloodstream in case of 
hazardous situations.  
The WAK has some limitations, although being the most important wearable prototype developed 
until now: the belt is rather bulky, heavy and not very ergonomic. Furthermore, although no data are 
available on overall power consumption of this device, it can most likely be estimated in at least 10 
W (the declared power consumption of just the pump unit is 5 W). Furthermore, two 9 V batteries are 
able to guarantee, in the best case, a power output of 20 Wh, which means a battery life not higher 
than 2 hours [33, 36].  
 
 
Figure 7. Schematic representation of the WAK 
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ViWAK 
The ViWAK (Vicenza Wearable Artificial Kidney), shown in Figure 8, is a wearable device for 
continuous flow peritoneal dialysis designed by Prof Ronco and the Italian company Medica Srl 
(Medolla (MO), Italy) [38].  
 
 
Figure 8. Schematic representation of the ViWAK 
 
The device is only a conceptual prototype. It is connected to the patient by a double lumen peritoneal 
catheter and includes a miniaturized rotary blood pump and a dialysate inflow/outflow line. A 
regenerating system of cartridges (active carbons and polystyrene resins) guarantees a small amount 
of the peritoneal fluid necessary for blood purification. There is also a filter for removing air bubbles 
and a palmtop as remote-control unit. The therapy involves the infusion of two liters of dialytic 
solution into the peritoneal cavity and, after about 2 h, the removal of the same solution which is 
regenerated by the perfusion through the four cartridges. The removal of excess water is performed 
by simply removing more peritoneal solution than the infused one. The palmtop allows the clinician 
to prescribe and monitor the therapy by providing real time information on cartridge status, flow 
conditions, pressures, and possibility of intervention on the treatment. The disadvantages are related 
to the fact that peritoneal dialysis is a less efficient therapy with respect to the extracorporeal blood 
purification. Furthermore, the fact that the required injection of bicarbonate and glucose has to be 
done manually is a limitation, together with the risk of pH instability of peritoneal solution are both 
limitations. 
 
AWAK 
Professor Lee and Roberts' research led to the development of the WAK automated (AWAK) 
prototype [39] (Figure 9), based on continuous peritoneal dialysis therapy with regeneration of the 
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peritoneal solution by a modified SORB cartridge (SORB™, SORB™ Technology, Inc., OK, USA). 
The peritoneal dialysis regeneration is performed at a rate of 4 l/h by the cartridge. Through a single-
lumen catheter, the peritoneal fluid flows in two phases, inside and outside the patient, using an 
external containment chamber. The device includes two modules, one for disposable components of 
the system (absorbing cartridges), and the other one for reusable components (part of power supply 
and pump for fluid infusion), that need to be changed monthly. The device weighs 250 g and, 
depending on the prototype, can be equipped with 750 g absorbing cartridges, used for a duration of 
7 h and a flow rate of 2 l/h, or with a cartridge by 1.7 kg, used for 12 h of treatment with a flow of 4 
l/h. As previously said for ViWAK, the main limitations regard the peritoneal dialysis, which is a less 
efficient therapy than the extracorporeal blood circulation one, and makes it necessary to use 
bicarbonate and glucose injection systems for electrolytic and acid-base equilibrium. 
 
Figure 9. Schematic representation of the AWAK 
 
WHF 
The Wearable Hemofiltration Device (WHF) (Figure 10) is a device developed by the group of Prof 
Gura and his team [40], that is able to achieve hemofiltration of blood by a semipermeable membrane. 
Hemofiltration is a modality which, like ultrafiltration, consists of the removal of plasma water 
(ultrafiltration) and solutes (convection) by an imposed pressure gradient inside the filter, and a 
replacement of part of this water by reinfusion of physiological solution directly into the 
extracorporeal circuit. The WHF, like the WAK, is a belt. The patient is connected to the device by a 
double-lumen venous catheter, coupled to a miniaturized blood pump and two micro-battery pumps 
for the regulation of the ultrafiltration flow and the anticoagulant infusion. The overall weight of the 
device is less than 1.5 kg, while the maximum blood flow is about 115 ml/min and ultrafiltration flow 
ranges from 120 to 288 ml/h. The amount of urea and creatinine (the most important marker for CKD) 
removed during a treatment with WHF is potentially lower than the one reachable during traditional 
dialysis treatment: for this reason, the device is more suitable for patients with congestive heart 
failure. 
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Figure 10. Schematic representation of the WHF 
 
RAD 
The RAD is a prototype based on the concept of renal assist device. Humes et al. [41] suggested to 
replace not only filtrative but also metabolic and endocrinologic functions of the kidney. The RAD 
(Figure 11) is composed of a filter and hollow-fiber cartridges containing human tubular cells derived 
from donor organs unsuitable for human transplantation, and has demonstrated promising results in 
clinical trials in acute kidney failure patients [PMID: 15458454]. However, this device cannot be 
applied alone for the moment, but it has to be used in parallel with a hemofiltration system, since it 
cannot remove excess water. 
 
 
Figure 11. Schematic representation of the RAD 
 
iNEPHRON 
Financed by the European community in 2010, and developed by an international consortium of 
research centers and private companies [42], iNephron (Figure 12) is a small dimensions prototype 
(10 cm x 6 cm x 4 cm). Blood purification is reached by filters that allow it to separate part of plasma 
from red blood cells, which is then further filtered to remove small and medium molecular weight 
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waste molecules. These filters, whose mass is between 30 and 50 g, are based on nanosorbents 
technology and provide selective absorption capacity of solutes. An integrated system for controlling 
the treatment and remote monitoring of patients is also provided. iNephron is for the moment only a 
basic and conceptual prototype which is under development. In the website [42], the developers 
declare that miniaturization of the device and integration with sensors and control functions are 
foreseen in a parallel running EU/FP7 project called Nephron+ [43], that is intended to be portable 
but not wearable. Although iNephron is a promising device, it needs to be further implemented.  
 
 
 
 
 
 
 
Figure 12. Schematic representation of the iNEPHRON and NephronPlus 
 
 
WAKMAN 
Professor Ronco’s group developed a conceptual prototype of a wearable device for ultrafiltration 
able to offer greater mobility to patients: the WAKMAN [44]. The WAKMAN is a wearable 
ultrafiltration system (Figure 13) based on a miniaturized circuit mounted on a specific jacket that 
includes a compact and lightweight integrated pump-suction unit. This device can run from 8 to 24 
hours and can be easily worn by the patient. Blood flow can be set between 50 and 80 ml/min, while 
the ultrafiltration flow rate is between 2 and 10ml/min and can be adjusted and personalized according 
to patients' needs. The device can be carried comfortably in the pocket of the jacket, leaving the 
patient free to perform much of their daily activities while the treatment is in progress. Compared to 
conventional peristaltic pumps, a piezoelectric components blood pump is used. However, the 
WAKMAN is a design exercise introducing some interesting concepts but never translated into a 
working prototype, and probably difficult to implement in some parts.  
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Figure 13. A) . Schematic representation of the WAKMAN; B) Intergrated unit pump-hemofilter; C) Remote control 
display 
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4. Normative and risk management 
 
4.1 European directive and Standards 
 
The wearable/portable ultrafiltration machine that is intended to be developed falls into the category 
of medical devices and, consequently, its design must guarantee mandatory requirements defined by 
European and national legislations. The European Directive defining the essential requirements that 
any medical device on the European market has to comply with, is the European Directive 93/42/EEC. 
This directive was then supplemented and amended by Directive 47/2007/EC, which considers also 
software as medical devices. In Directive 93/42/EEC, first of all it is defined what a medical device 
is:  
Medical device means any instrument, apparatus, appliance, software, material or other article, 
whether used alone or in combination, including the software intended by its manufacturer to be used 
specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, 
intended by the manufacturer to be used for human beings for the purpose of: 
• diagnosis, prevention, monitoring, treatment or alleviation of disease, 
• diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, 
• investigation, replacement or modification of the anatomy or of a physiological process, 
• control of conception,  
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function by 
such means. 
Two annexes of the Directive are particularly important:  
• Annex I, which defines the essential requirements that must be respected to produce, trade 
and inspect a CE marked medical device,  
• Annex IX, which classifies medical devices into four classes; in particular, a wearable and 
portable device for ultrafiltration falls within class IIb, that includes all non-invasive devices 
intended for modifying the biological or chemical composition of blood, other body liquids or 
other liquids intended for infusion into the body. 
 
Class IIb devices must be considered separately from the non-contact devices, since they are 
indirectly invasive and modify substances that will eventually be infused into the body. This 
definition covers mostly the more sophisticated elements of extracorporeal circulation sets, dialysis 
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systems and auto transfusion systems as well as devices for extracorporeal treatment of body fluids 
which may or may not be immediately reintroduced into the body, including, where the patient is not 
in a closed loop with the device. 
One of the most important concepts defined in the directive regarding the design of a medical device, 
even before the provision of therapeutic or diagnostic efficacy, is that it must be safe: this means to 
reduce to an acceptable minimum risk the probability of inducing any hazardous situation to the 
patient or the environment. Thus, before the design phase of any device, and in particular of medical 
ones, a deep study needs to be carried out in order to perform an appropriate risk management 
analysis.  
Risk management is an efficient and universally recognized method to identify the potential 
hazardous situations and ensure a sufficient level of safety of biomedical devices. The main aim of 
this methodology is to quantify, and then, during the production cycle, minimize, the inevitable level 
of risk related to operations and use of a medical device. In order to respect that, technical standards 
regarding risks associated with the use of a medical device have been considered. In particular, the 
standard ISO/IEC 14971 (International Organization for Standardization ISO and International 
Electrotechnical Commission) is specifically dedicated to the risk management process for medical 
devices, defining the guidelines to follow during this process. Of course, since the criteria outlined in 
the standard have a general meaning, they have to be adapted to the particular type of the considered 
medical device. An important aspect underlined in the standard is the fact that possible risks 
associated with the device should be analyzed in several ways: the risk should be considered 
acceptable both on the technical/engineering and clinical or biological levels. It is therefore necessary 
to face the process in a multi-disciplinary and multi-professional approach, able to analyze the 
problem from different points of view. 
It is necessary to highlight how there are no specific standards treating miniaturized portable/wearable 
medical devices for extra-corporeal blood ultrafiltration, so the technical standards concerning 
medical electrical equipment need to be applied and adapted to the particular case. 
The risk management process has been performed considering the following standards: 
• IEC 60601-1: general harmonized technical standard concerning the safety and effectiveness 
of medical electrical equipment; 
• IEC 60601-1-1: collateral standard concerning safety requirements for medical electrical 
systems; 
• IEC 60601-1-4: collateral standard concerning programmable electrical medical systems; 
• IEC 60601-1-6: collateral standard concerning usability of medical electrical equipment; 
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• IEC 60601-1-8: collateral standard concerning general requirements, tests and guidance for 
alarm systems in medical electrical equipment; 
• IEC 60601-1-11: collateral standard concerning requirements for medical electrical 
equipment and medical electrical systems used in the home healthcare environment; 
• IEC 60601-2-16: collateral standard concerning particular requirements for the safety of 
haemodialysis, haemodiafiltration and haemofiltration equipment; 
• ISO/IEC 12207: technical standard concerning systems and software engineering - software 
life cycle processes; 
• CEI/EN 62366: technical standard concerning the application of usability engineering to 
medical devices; 
• ISO 8637: technical standard concerning specific requirements for cardiovascular implants 
and artificial organs – haemodialysers, haemodiafilters, haemofilters and 
haemoconcentrators. 
 
The risk management process has been carried out to comply with the European Directive 93/42/EEC 
and all the technical standards listed above.  
 
4.2 Risk management 
The aim of the risk management process is to identify harms for patients derived from potential 
hazardous situations and their causes. This process is usually necessary to select all the hardware 
components devoted to safety for the prototype to be developed.  
The clinical risk assessment is based on the device operating in open chain, meaning that no 
monitoring systems and/or feedback protection are applied. As a next step, after assembling and 
prototyping the system, other types of risks, specifically related to the use of actuators and sensors, 
may be considered in addition to the clinical/operational risks.  
The categories of risks are: 
• hardware 
o mechanical 
o electrical 
• software (based on technical standard CEI EN 62304) 
• environmental 
• physical 
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• chemical 
In Figure 14, a sequencing scheme of the risk management process is reported, according to the 
technical standard ISO/IEC 14971.  
 
Figure 24: Overview of risk management activities as applied to medical devices 
As shown in the graph, the key stages of the risk management process are: 
33 
 
• risk analysis; 
• risk evaluation; 
• risk control; 
• implementation and verification of control measures; 
• acceptability of residual risk. 
 
According to the terminology adopted in the standard ISO/IEC 14971, designers are requested firstly 
to identify a list of known and foreseeable hazards, as sources of harm, that are directly associated 
with the specific medical device. A situation in which people, properties, or the environment are 
exposed to a hazard is called a hazardous situation. The risk associated with each hazardous situation 
has to be estimated using literature. Usually, the quantification of the risk results from the product of 
two components: the severity of the harm, which consists of the consequences of the harm that is 
generated by each hazard situation, and the probability of occurrence of that harm. If this score for 
risk quantification is evaluated as too high, a risk reduction is necessary. In this case, risk control 
measures shall be applied and the related residual risk shall be re-evaluated. This process has to be 
followed in a recursive way, until the final residual risk is judged acceptable. In order to have a 
consistent and reproducible method, an appropriate evaluation scale has been identified to define 
severity, probability, and the resulting risk. 
Based on these guidelines, standards (ISO/IEC 14971 and [45]) and literature [46], an assessment of 
possible harms to the patient deriving from clinical/operational risks, which means only deriving from 
the clinical use of the WUF, not considering any environmental damage, was done. The list of 
possible harms is listed in the left column of Table 3. For each harm, the hazardous situations and 
their causes have been associated through a top down fault free analysis: it is a technique for system 
safety analysis that starts defining the harms and goes down to define possible causes. The definition 
of these circumstances allowed filling in Table 3.     
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Patient harm Hazardous situation Hazardous situation causes 
Vessel walls damage and thrombosis  Vascular access (catheter) 
malfunction 
Catheter displacement  
Catheter tip touches the vessel wall 
Catheter clotting 
Blood flow rate too high for the 
catheter 
Excessive bleeding Excessive level of anticoagulant into 
the blood stream 
Excessive continuous administration 
of anticoagulant 
Excessive bolus administration of 
anticoagulant 
The concentration of anticoagulant in 
the solution to be infused is excessive 
(preparation error) 
The ratio between anticoagulant 
continuous flow rate and blood flow 
rate is out of acceptable clinical range 
Error during setting of parameters in 
the device by the user 
Embolism/thrombosis  Air infusion in the extracorporeal 
circuit 
Cracking or rupture of extracorporeal 
circuit connectors  
 
Cracking or rupture of the catheter 
 
Excessive negative pressure in access 
line  
Incomplete circuit filling during 
priming phase 
Blood loss (1) Blood coagulation in the 
extracorporeal circuit 
Contact between blood and external 
surfaces 
Insufficient anticoagulant 
administration (control error) 
Insufficient anticoagulant bolus 
administration (control error) 
Insufficient concentration of 
anticoagulant in the prepared solution 
to be administered (error in solution 
preparation) 
Ratio between anticoagulant flow rate 
and blood flow rate out of acceptable 
clinical range 
Error during setting of 
anticoagulation therapy parameters in 
the device by the user 
Anticoagulant reserve exhausted 
Prolonged treatment interruption: out 
of battery 
 
Prolonged treatment interruption: 
blood pump stopped 
 
Blood flow rate too slow 
 
Patient hematocrit too high 
 
Treatment hematocrit too high: ratio 
between UF and blood flow rates 
excessively high 
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Blood loss (2) Blood loss in UF compartment Filter membrane cracking or rupture 
due to too high transmembrane 
pressure 
Blood loss (3) Blood loss from extracorporeal 
circuit  
Catheter displacement  
Disconnection of vascular 
access/lines/filter connectors 
Rupture of vascular access/lines/filter 
connectors 
Lines/filter rupture: internal pressure 
too high  
Lines/filter rupture: external 
mechanical stress (compression, 
traction, twisting, shearing, vibration) 
Vascular access/lines/filter 
connectors not properly connected 
External obstruction in access line 
External obstruction in pre-filter line 
External obstruction in return line 
Hyperthermia Blood overheating: heat exchange 
with the external environment 
Environmental temperature too high 
Contact with high temperature fluids 
Contact with high temperature 
surfaces 
Device combustion 
Hypothermia 
  
Blood overcooling: heat exchange 
with the external environment 
Environmental temperature too low 
Contact with low temperature 
external elements 
Hemolysis 
  
  
  
  
  
  
  
Red blood cells rupture High shear stress: blood viscosity too 
high  
High shear stress: blood flow rate too 
high 
Excessive blood pressure: obstruction 
of vascular access/lines/filter 
Excessively high blood pressure: 
vascular access/lines/filter clotting 
Hyperthermia 
Mechanical compression stress due to 
blood pump 
Mechanical shear stress due to blood 
pump  
Chemical and/or biological residues 
Hypervolemia 
  
Error during setting of UF parameters 
in the device by the user 
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The removed plasma water (UF) 
volume is less than the prescribed 
one 
UF flow rate and/or UF volume 
removed is lower than prescribed 
ones: error of treatment process (the 
UF pump) 
Decreased filter efficiency (e.g. 
clotting) 
Treatment stop/discontinuation  
Ultrafiltration tank is full 
UF line disconnection 
Rupture of UF line connectors  
Rupture of UF line: excessive inner 
pressure 
Rupture of UF line: external 
mechanical stress (compression, 
traction, twisting, shearing, vibration) 
UF connectors/lines not properly 
connected 
Rupture of UF tank 
Hypovolemia  The removed plasma water volume is 
more than the prescribed one 
Error during setting of UF parameters 
in the device by the user 
  
UF flow rate and/or UF volume 
removed is higher than prescribed 
ones: error of treatment process (the 
UF pump) 
 Table 3. Risk analysis related to the use of the WUF 
 
After having defined the causes possibly leading to harms, it was necessary to quantify the risk that 
any of these causes may generate during normal treatment with the medical device. The risk’s 
estimation, as explained, can be obtained by the product of two components: severity and probability 
related to harms. These two factors are usually defined based on the analysis derived from two scales 
of values. If the result of this product exceeds a risk-tolerance threshold value defined by the designer, 
it is necessary to reduce the overall risk of a single event through appropriate arrangements. This 
process has to be repeated until the residual risk level assigned to each harm is acceptable or reaches 
a level of risk defined as ALARP, (as low as reasonably practicable). “ALARP” identifies a reduced 
risk that can ensure the maximum level of safety achievable taking into considerations even economic 
and technical aspects.  
The scales of values used in this project to quantify severity and probability of risks are reported in 
Table 4 and Table 5 [45]. 
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Severity 
Level Assigned score Generic description 
Catastrophic 5 Death 
Critical 4 Permanent impairment or life-threatening injury 
Serious 3 Injury or impairment requiring professional medical 
intervention 
Minor 2 Temporary injury or impairment not requiring professional 
medical intervention 
Negligible 1 Inconvenience or temporary discomfort; no injury 
Table 4. Levels of severity of risk 
 
Probability 
Level Assigned score Probability of the event 
Frequent 5 ≥ 10-3 
 
Probable 4 < 10-3 e ≥ 10-4 
 
Occasional 3 < 10-4 e ≥ 10-5 
Remote 2 < 10-5 e ≥ 10-6 
Improbable 1 < 10-6 
Table 5. Levels of probability of risk 
Based on these levels, a cross table has been identified in order to define in a clear and efficient 
manner the overall risk levels to consider (Table 6). 
 
  Severity 
  Catastrophic Critical Serious Minor Negligible 
Probability 
Frequent B A A A A 
Probable B B A A A 
Occasional C B B A A 
Remote C B B B A 
Improbable C C C B B 
Table 6. Definition of risks level (A=unacceptable, B=ALARP (as low as reasonably possible), C=acceptable). 
 
Table 7, that describes all the identified harms and hazardous situations, together with associated 
levels of risk, has been completed in collaboration with the clinicians of the Department of 
Nephrology, Dialysis and Transplantation of the San Bortolo Hospital in Vicenza. 
38 
 
HAZARDOUS SITUATION 
HAZARDOUS SITUATION 
CAUSES 
S
E
V
E
R
IT
Y
 
L
E
V
E
L
 
O
F
 
H
A
Z
A
R
D
O
U
S
 
S
IT
U
A
T
IO
N
 C
A
U
S
E
 
 P
R
O
B
A
B
IL
IT
Y
 
O
F
 
H
A
Z
A
R
D
O
U
S
 
S
IT
U
A
T
IO
N
 C
A
U
S
E
 
R
IS
K
 A
S
S
E
S
S
M
E
N
T
 O
F
 H
A
Z
A
R
D
O
U
S
 
S
IT
U
A
T
IO
N
 C
A
U
S
E
 
W
O
R
S
T
 
C
A
S
E
 
O
F
 
H
A
Z
A
R
O
D
U
S
 
S
IT
U
A
T
IO
N
 
Vascular access (catheter) malfunction Catheter displacement  2 2 B 
B 
 Catheter tip touches the vessel wall 1 3 C 
 Catheter clotting 1 2 C 
 Blood flow rate too high for the catheter 1 1 C 
Excessive level of anticoagulant into the 
blood stream 
Excessive continuous administration of 
anticoagulant 
4 
1 
B 
B 
 Excessive bolus administration of 
anticoagulant 
1 
B 
 The concentration of anticoagulant in the 
solution to be infused is excessive 
(preparation error) 
2 
B 
 The ratio between anticoagulant 
continuous flow rate and blood flow rate is 
out of acceptable clinical range 
2 
B 
 Error during setting of parameters in the 
device by the user 
2 
B 
Air infusion in the extracorporeal circuit Cracking or rupture of extracorporeal 
circuit connectors  
5 
2 A 
A 
 Cracking or rupture of the catheter 2 A 
 Excessive negative pressure in access line  3 A 
 Incomplete circuit filling during priming 
phase 
3 A 
Blood coagulation in the extracorporeal 
circuit 
Contact between blood and non-self 
surfaces 
3 
3 B 
B 
 Insufficient anticoagulant administration 
(control error) 
1 C 
 Insufficient anticoagulant bolus 
administration (control error) 
1 C 
 Insufficient concentration of anticoagulant 
in the prepared solution to be administered 
(error in solution preparation) 
1 C 
 Ratio between anticoagulant flow rate and 
blood flow rate out of acceptable clinical 
range 
1 C 
 Error during setting of anticoagulation 
therapy parameters in the device by the user 
1 C 
 Anticoagulant reserve exhausted 2 B 
 Prolonged treatment interruption: out of 
battery 
 
2 B 
 Prolonged treatment interruption: blood 
pump stopped 
 
2 B 
 Blood flow rate too slow 
 
2 
1 B 
 Patient hematocrit too high 
 
2 
1 B 
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 Treatment hematocrit too high: ratio 
between UF and blood flow rates 
excessively high 
2 
1 C 
Blood loss in UF compartment Filter membrane cracking or rupture due to 
too high transmembrane pressure 
4 2 B B 
Blood loss from extracorporeal circuit  Catheter displacement  5 2 A 
A 
 Disconnection of vascular 
access/lines/filter connectors 5 2 A 
 Rupture of vascular access/lines/filter 
connectors 5 2 A 
 Lines/filter rupture: internal pressure too 
high  5 2 A 
 Lines/filter rupture: external mechanical 
stress (compression, traction, twisting, 
shearing, vibration) 
5 1 B 
 Vascular access/lines/filter connectors not 
properly connected 5 2 A 
 External obstruction in access line 2 3 B 
 External obstruction in pre-filter line 3 3 B 
 External obstruction in return line 3 3 B 
Blood overheating: heat exchange with the 
external environment 
Environmental temperature too high 
4 
1 B 
B 
 Contact with high temperature fluids 1 B 
 Contact with high temperature surfaces 2 B 
 Device combustion 1 B 
Blood overcooling: heat exchange with the 
external environment Environmental temperature too low 
3 
3 B 
B 
 
Contact with low temperature external 
elements 2 B 
Red blood cells rupture High shear stress: blood viscosity too high  
2 
3 B 
B 
 High shear stress: blood flow rate too high 2 B 
 
Excessive blood pressure: obstruction of 
vascular access/lines/filter 4 B 
 
Excessively high blood pressure: vascular 
access/lines/filter clotting 2 B 
 Hyperthermia 2 B 
 
Mechanical compression stress due to 
blood pump 4 B 
 Mechanical shear stress due to blood pump  4 B 
 Chemical and/or biological residues 1 C 
The removed plasma water volume is less 
than the prescribed one 
Error during setting of UF parameters in the 
device by the user 
2 
3 B 
B 
 
UF flow rate and/or UF volume removed is 
lower than prescribed ones: error of 
treatment process (UF pump) 
4 B 
 Decreased filter efficiency (e.g. clotting) 4 B 
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 Treatment stop/discontinuation  4 B 
 Ultrafiltration tank is full 3 B 
 UF line disconnection 2 B 
 Rupture of UF line connectors  1 C 
 
Rupture of UF line: excessive inner 
pressure 2 B 
 
Rupture of UF line: external mechanical 
stress (compression, traction, twisting, 
shearing, vibration) 
1 C 
 
UF connectors/lines not properly 
connected 2 B 
 Rupture of UF tank 2 B 
The removed plasma water volume is more 
than the prescribed one 
Error during setting of UF parameters in the 
device by the user 
4 
2 B 
A  UF flow rate and/or UF volume removed is 
higher than prescribed ones: error of 
treatment process (the UF pump) 
3 A 
Table 7. Risk quantification of the causes of hazardous situation  
Among the possible causes of hazardous situations, particular attention must be paid on the ones with 
the highest level of risk (A). In such cases, technological adjustments need to be applied in order to 
reduce the risk at least from unacceptable (A) to as low as reasonably possible (B).    
Table 8 shows how the selected technological adjustments intended to be applied to the WUF (which 
will be treated in details in the next paragraph) allow reducing the risks of unacceptable hazardous 
situations (A) to ALARP (B) or even to acceptable (C). 
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Catheter displacement  B 
B 
Access/return pressure exceeding 
lower/upper limit 
 
Blood flow exceeding lower limit 
 
Access pressure exceeding lower limit 
Access and return pressure 
sensors 
 
 
Blood flowmeter (or blood flow 
estimation) 
 
Access pressure sensors 
C 
Catheter tip touches the 
vessel wall 
C 
Catheter clotting C 
Blood flow rate too 
high for the catheter C 
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Excessive continuous 
administration of 
anticoagulant 
B 
B 
Anticoagulant flow rate exceeding 
upper limit 
Anticoagulant flowmeter 
 
Anticoagulant administration 
monitoring system 
C 
Excessive bolus 
administration of 
anticoagulant 
B 
Anticoagulant bolus exceeding upper 
limit 
Anticoagulant administration 
monitoring system 
The concentration of 
anticoagulant in the 
solution to be infused is 
excessive (preparation 
error) 
B 
Diagnostic analysis  
The ratio between 
anticoagulant 
continuous flow rate 
and blood flow rate is 
out of acceptable 
clinical range 
B 
Error during setting of 
parameters in the 
device by the user 
B 
Cracking or rupture of 
extracorporeal circuit 
connectors  
A 
A 
Air flow (ml/kg min) exceeding upper 
limit 
 
Air bolus (ml/kg) exceeding upper 
limit 
Air bubble detector B 
Cracking or rupture of 
the catheter 
A 
Excessive negative 
pressure in access line  
A 
Incomplete circuit 
filling during priming 
phase 
A 
Contact between blood 
and non-self surfaces 
B 
B 
Pre-filter/return/transmembrane 
pressures exceeding upper limit 
Pre-filter and return pressure 
sensors 
C 
Insufficient 
anticoagulant 
administration (control 
error) 
C 
Anticoagulant flow rate exceeding 
lower limit 
Anticoagulant flowmeter 
Anticoagulant administration 
monitoring system 
Insufficient 
anticoagulant bolus 
administration (control 
error) 
C 
Anticoagulant bolus exceeding lower 
limit 
Anticoagulant administration 
monitoring system 
Insufficient 
concentration of 
anticoagulant in the 
prepared solution to be 
administered (error in 
solution preparation) 
C 
Pre-filter/return/TMP/drop pressure 
exceeding upper limit 
Access and return pressure 
sensors 
Ratio between 
anticoagulant flow rate 
and blood flow rate out 
of acceptable clinical 
range 
C 
Error during setting of 
anticoagulation 
therapy parameters in 
the device by the user 
C 
Anticoagulant reserve 
exhausted 
B 
Anticoagulant flow rate exceeding 
lower limit 
Anticoagulant flowmeter 
 
Position sensor (syringe plunger)  
 
Anticoagulant administration 
monitoring system 
Prolonged treatment 
interruption: out of 
battery 
B Battery level exceeding lower limit  
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Prolonged treatment 
interruption: blood 
pump stopped 
 
B 
Blood flow and/or blood pump speed 
equal to zero 
Blood line flowmeter 
 
Blood pump speed sensor 
 
Pressure sensors 
Blood flow rate too 
slow 
 
C 
Blood flow exceeding lower limit 
(non-zero) 
Patient hematocrit too 
high 
 
C 
Hematocrit value (IR system) 
exceeding upper limit 
Hematocrit sensor  
Treatment hematocrit 
too high: ratio between 
UF and blood flow 
rates excessively high 
C 
UF flow over blood flow rate 
(filtration fraction) exceeding upper 
limit 
Blood line flowmeter 
 
UF line flowmeter 
 
UF volume monitoring system 
Filter membrane 
cracking or rupture due 
to too high 
transmembrane 
pressure 
B B 
Blood in UF compartment exceeding 
upper limit 
Blood leak detector sensor C 
Catheter displacement  A 
A 
Access, Pre-
filter/return/UF/TMP/drop pressures 
exceeding upper limit 
 
Humidity 
Access, pre-filter, return and UF 
pressure sensors 
 
Flowmeters 
 
Humidity sensors 
B 
Disconnection of 
vascular 
access/lines/filter 
connectors 
A 
Rupture of vascular 
access/lines/filter 
connectors 
A 
Lines/filter rupture: 
internal pressure too 
high  
A 
Lines/filter rupture: 
external mechanical 
stress (compression, 
traction, twisting, 
shearing, vibration) 
B 
Vascular 
access/lines/filter 
connectors not 
properly connected 
A 
External obstruction in 
access line B 
External obstruction in 
pre-filter line B 
External obstruction in 
return line B 
Environmental 
temperature too high B 
B 
Blood temperature exceeding upper 
limit 
Temperature sensor B 
Contact with high 
temperature fluids B 
Contact with high 
temperature surfaces B 
Device combustion B 
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Environmental 
temperature too low B 
B 
Blood temperature exceeding lower 
limit 
Temperature sensor C Contact with low 
temperature external 
elements 
B 
High shear stress: 
blood viscosity too 
high  
B 
B 
Diagnostic analysis and/or pressures 
assessment 
Access, pre-filter, return, UF 
pressure sensors 
 
Hematocrit sensor 
  
 
Temperature sensor 
B 
High shear stress: 
blood flow rate too 
high 
B 
Excessive blood 
pressure: obstruction of 
vascular 
access/lines/filter 
B 
Hematocrit value (IR system) 
exceeding lower limit 
Excessively high blood 
pressure: vascular 
access/lines/filter 
clotting 
B 
Hyperthermia B 
Mechanical 
compression stress due 
to blood pump 
B 
Diagnostic analysis 
Mechanical shear 
stress due to blood 
pump  
B 
Chemical and/or 
biological residues C 
Error during setting of 
UF parameters in the 
device by the user 
B 
B 
UF flow rate and/or volume exceeding 
lower limit 
UF volume monitoring system:  
UF flowmeter 
Volumetric system 
Gravimetric system (load cells) 
 
Pre-filter return and UF pressure 
sensor 
C 
UF flow rate and/or UF 
volume removed is 
lower than prescribed 
ones: error of treatment 
process (UF pump) 
B 
Decreased filter 
efficiency (e.g. 
clotting) 
B TMP pressure exceeding upper limit 
Treatment 
stop/discontinuation  B Blood flow rate exceeding lower limit 
Ultrafiltration tank is 
full B UF pressure out of range 
UF line disconnection B UF pressure out of range 
Rupture of UF line 
connectors  C 
Abnormal pressure values, humidity 
Rupture of UF line: 
excessive inner 
pressure 
B 
Rupture of UF line: 
external mechanical 
C 
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stress (compression, 
traction, twisting, 
shearing, vibration) 
UF connectors/lines 
not properly connected B 
Rupture of UF tank B 
Error during setting of 
UF parameters in the 
device by the user 
B 
A 
UF flow rate and/or volume exceeding 
upper limit 
UF volume monitoring system:  
UF flowmeter 
Volumetric system 
Gravimetric system (load cells) 
B 
UF flow rate and/or UF 
volume removed is 
higher than prescribed 
ones: error of treatment 
process (the UF pump) 
A 
Table 8. Parameters to monitor during the treatment e hardware components possibly to be applied in order to reduce 
the risk associated to the causes of hazardous situations 
 
This analysis allows identifying possible components to equip the wearable/portable system with in 
order to keep risk to a minimum. In particular, the hardware components which would guarantee a 
reduction of the overall risk of specific hazardous situations, and then harms, are: 
• Air sensor able to read air bubbles in blood line before reinfusion to the patient; 
• Blood leak detector able to detect blood loss due to membrane rupture; 
• Three pressure sensors to preventively avoid blood loss from the blood circuit due to 
disconnections or blood coagulation;  
• One pressure sensor in the ultrafiltrate line to detect coagulation in the filter potentially 
leading to blood loss; 
• Humidity sensors to detect blood loss; 
• Fluid balance monitoring system to check the plasma water volume removed from the patient; 
• Temperature sensor to monitor excessive temperature variations; 
• A sensor, or a reliable estimation strategy, for monitoring the heparin flow and a sensor 
detecting when the tank for heparin is empty; 
• Hematocrit sensor to measure the hematocrit levels in the extracorporeal circuit; 
• System for monitoring blood flow. 
This list of components has been further skimmed considering that: 
• Risks for hazardous situation, whose related risk is not worse than “ALARP”, should take into 
account also aspects related to costs, overall dimensions and environment; 
• If two or more components have the same function, it has been considered sufficient to apply 
only one of these components if safety requirements are respected.  
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In such context, the humidity sensor has the same aim as pressure sensors, which is to detect possible 
blood loss due to disconnections of the extracorporeal circuit components or blood coagulation. 
Furthermore, the humidity sensor would be affected by environmental conditions, possibly leading 
to wrong measurements. For these reasons, no humidity sensor will be adopted. 
The hematocrit is the percentage in volume of red blood cells in blood. Since the hematocrit variation 
along the treatment duration in a standard ultrafiltration therapy has been considered very low, no 
sensor for detection of hematocrit levels is used in the device presented in this thesis. 
Regarding the system for monitoring the blood flow, initially a flowmeter was thought to be used. 
Anyway, the measurement of blood flow can be both estimated by variations of pressure inside the 
circuit and measured starting from the velocity of the blood pump, in case such a pump is a volumetric 
one. Taking also into considerations that a flowmeter would be expensive and quite bulky, it has been 
decided not to adopt it in the device. A similar reasoning justifies the choice not to adopt a sensor for 
monitoring the heparin flow which, in case a volumetric pump is employed, can be easily estimated. 
Based on this further analysis, the final list of components to be integrated in the wearable device and 
which can guarantee an adequate level of safety to patients is: 
• Air sensor; 
• Blood leak detector; 
• 4 pressure sensors: 
o Access pressure sensor; 
o Pre-filter pressure sensor; 
o Return pressure sensor; 
o Ultrafiltrate pressure sensor; 
• Fluid balance monitoring system; 
• A sensor detecting when the tank for heparin is empty; 
• Temperature sensor. 
It is apparent that the detection of a hazardous situation by itself does not lead to a direct risk reduction 
associated with it. For this reason, for every hazardous situation, specific responding actions need to 
be performed. These actions include:  
• closure of a clamp (safety valve) placed before the blood returns to the patient;  
• stop of the blood pump; 
• stop of the ultrafiltration pump;  
• acoustic signal when alarms or warnings are detected. 
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The presence of a clamp is crucial because, when a hazardous situation is detected, it leads to an 
immediate occlusion of the extracorporeal blood circulation. A clamp must be capable of occluding 
the circuit through which blood flows, thereby isolating the problem and significantly reducing direct 
and indirect risk to patients. 
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5. Components for a wearable device 
 
Based on clinical indications from the staff of the Department of Nephrology, Dialysis and 
Transplantation of the San Bortolo Hospital of Vicenza and the International Renal Research Institute 
of Vicenza, and the literature review of existing or proposed prototypes of portable devices as well 
as conventional treatment machines, it has been possible to identify the requirements that a modern 
wearable and portable device for extracorporeal ultrafiltration must meet. Subsequently, the most 
suitable technologies for the components considered essential for the development of the WUF have 
been selected.  
As mentioned, in general the WUF must provide extracorporeal circulation of blood and ultrafiltrate 
removal by means of pumps. Clearly, the device should be wearable, wireless and independent from 
the electrical power outlet at least for periods lasting long enough not to pose serious limitations to 
patients’ usual mobility habits. The WUF is intended to be used for continuous ultrafiltration therapy, 
i.e. 24 hours a day: in such a condition, the apparatus may consume large amounts of energy which 
imposes that adequate energy sources are available and a careful design of components so as to 
guarantee relevant energy savings. In addition to such requirements, miniaturization, ergonomics, and 
low weight are obviously of paramount importance and need to be taken into account during all the 
design phases. 
Going into details, for the specific treatment considered, the requested blood flow is about 50 ml/min. 
It is essential that the vascular access adopted avoids infections and clots formation; it is also 
necessary that connection and disconnection are easy to perform. The extracorporeal circulation has 
to be made of anti-thrombogenic materials and have a low priming volume. The circuit must be 
provided with adequate safety measures for the patient. The filter must be small in size, about one-
tenth of normal filters used in standard ultrafiltration therapies. The membranes of the filter must be 
non-thrombogenic, or at least as low as possible, in order to minimize the risk of coagulation.  
The device must be able to remove an amount of ultrafiltrate volume similar to one physiologically 
removed from the kidneys. The removal of excess fluid will result in a better control of hypertension. 
The volume to be removed is then between 1.5 and 2 liters in 24 hours (or even less). The therapy 
allows also to eliminate substances such as sodium, thereby helping to overcome some dietary 
limitations of the patient.  
When blood encounters artificial materials, the coagulation system of blood is immediately activated, 
inducing the coagulation cascade. In order to reduce this phenomenon during the extracorporeal blood 
circulation, a controlled and continuous infusion of anticoagulation drugs, such as heparin, has to be 
administered into the circuit. The estimated heparin flow is between 1 and 2.5 ml/h.     
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In order to allow patient to wear the device and to walk without interfering with daily activities, it 
must have a light and ergonomic design.  
Finally, the device should be designed to be run autonomously and monitored remotely by medical 
staff. Indeed, the device controller should not only allow setting up the therapy and running it, but 
should also allow performing a continuous or on-demand data logging for monitoring purposes. The 
prescription of operative parameters and treatment data visualization must be easily accessible 
through a comprehensive software interface too. 
Clearly, for a wearable/portable device it is necessary to include in the design only what is strictly 
necessary. As previously stressed, some of the components that have been integrated in the system 
have been chosen among those available commercially. A specific initial effort has been devoted to 
define which of them could be: 
• Disposables (replaced after each treatment), which are preferable for hygienic reasons; 
• Not disposables (not replaced after each treatment), for economic reasons. 
A comprehensive seek on the market of such off-the-shelf components has been carried out, limiting 
the exploration to components manufactured in Italy or manufactured but international companies 
with Italian distributors in order to meet the strict requirements imposed by the administrative leader 
of the “RAP” project. After the identification of all the possible components suitable for the project, 
the selection of the best ones has been based on clinical, technical and economic evaluations. On the 
other hand, for some “critical” components it has been necessary to perform specific and thorough 
investigations because either they were not commercially available or not enough studied in literature. 
After such investigations, described later in this chapter, it has been determined whether these 
components needed to be adopted, if they could be selected among off-the-shelf products or if they 
should be customized or even designed specifically for this application. 
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5.1 General scheme of the extracorporeal circuit 
Considering the basic requirements previously stated and results from the risk management analysis, 
it has been possible to define the general scheme of the WUF to be developed. It is represented in 
Figure 15. 
 
 
Figure 15. General scheme of the WUF 
 
Each component shown in the scheme will be described and analyzed in details in the following 
paragraphs, justifying its choice and selection.   
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5.2 Off-the-shelf components: requirements and selection 
The analysis and choice of the off-the-shelf components of the WUF have been carried out applying 
a methodological approach consisting of the following phases: 
• functional analysis of each component; 
• definition of specifications to be met; 
• identification of available technologies; 
• identification of the components available in the market that integrate the identified 
technologies and that meet design specifications. 
Off-the-shelf hydraulic components will be first described, then off-the-shelf electric and electronic 
components, including sensors end controllers, will be discussed. The components will be presented 
in the following order:  
- Off-the-shelf hydraulic components 
- Off-the-shelf sensors 
- Off-the-shelf controllers  
- Off-the-shelf additional electric and electronic devices (boards and sensor conditioning 
system) 
 
5.2.1 Off-the shelf hydraulic components 
 
The off-the-shelf hydraulic include the vascular access, the hemofilter, tubes and ultrafiltration pump.  
Vascular access 
The vascular access is the device through which blood is extracted and then reinfused into the patient.  
In general, vascular accesses can be classified as temporary or permanent. The temporary ones are 
mainly used for patients suffering from acute kidney injury or for patients with chronic kidney disease 
waiting for permanent access; the permanent ones are instead specifically used for patients 
undergoing dialysis treatments continually. Since the aim of the WUF is to treat patients in a 
continuous form, temporary accesses will not be described. The main permanent vascular accesses 
are arteriovenous fistula (AVF), arteriovenous graft and central venous catheter (CVC). 
The AVF is the most used permanent vascular access type for extracorporeal treatments (such as 
hemodialysis). In order to provide an extracorporeal blood flow high enough to perform blood 
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purification, a surgical anastomosis between a vein and an artery is made. Usually, it is applied in 
peripheral vessels in arms (Figure 16).  
  
Figure 16. Schematic example of an arterio-venous fistula 
The arterio-venous graft consists of a prothesis surgically connected with the artery and the vein 
(Figure 17). The most used material is Polytetrafluoroethylene (PTFE). This type of vascular access 
is usually applied when an AVF cannot be carried out in the patient’s arm.  
  
Figure 17. Schematic example of an arterio-venous graft 
 
Fistulas (AVF and graft) are applied in the arm and would not be the best solution for a WUF, since 
they would not allow freedom of movement and to perform normal daily activities for patients. 
For these reasons, the central venous catheter (CVC) has been considered the best solution (Figure 
18).  
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Figure 18. Central venous catheter positioned in jugular vein 
A catheter is inserted through the skin into a large vein (jugular, femoral or subclavian). The catheter 
is then threaded through this vein until it reaches a large vein near the heart. The type of catheter used 
in blood purification therapies is “dual-lumen”: in the proximal part (the part remaining outside of 
the skin, the so-called exit side), two ports (red and blue colored) are present, one for extraction and 
the other one for reinfusion of blood to the same vein of patients. Different designs of dual lumen 
catheter have been developed by different companies. In particular, different cross sections are 
represented in Figure 19. 
 
 
Figure 19. Design examples of dual lumen catheters 
 
The most used configuration is the double “D” dual lumen, since it allows a good hemodynamics 
inside the catheter.  
Particular attention has been paid on the definition of the minimum size of the catheter. In particular, 
based on the WUF prescribed blood flow, the length and the diameter of the channels have been 
determined for this specific aim. The details are discussed in Appendix A. A double “D” lumen 
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catheter (Figure 20), positioned in the jugular vein, with a length of 19 cm and a lumen of 10 French, 
corresponding to an external diameter of 3.34 mm, has been chosen.    
 
 
Figure 20. Selected dual lumen catheter for the WUF 
Hemofilter 
 
The importance of the hemofilter in performing the ultrafiltration therapy has been already stated. An 
ideal hemofilter for a WUF must have the following features: 
• high biocompatibility; 
• inner membrane with an appropriate ultrafiltration coefficient; 
• good ratio between exchanging surface and total volume; 
• small dimensions; 
• limited priming volume; 
• minimum production costs. 
The most important characteristic of a hemofilter is biocompatibility. A filter can be considered 
biocompatible if its use does not have any adverse clinical effect on a patient such as headache, 
nausea, anxiety, pruritus, leukocyte variation, complement activation (complex of proteins 
responsible for the immune system) or granulocytes activation. In particular, the hemofilter to be 
applied must ensure hemocompatibility, complying with the standard UNI EN ISO 10993-4 which 
regulates in vitro and in vivo tests for this type of biomedical devices and provides tests related to 
thrombosis, coagulation, platelet function, hematological and immunological parameters.  
The ultrafiltration coefficient (Kuf) is an important parameter for the choice of the hemofilter and 
indicates the amount of maximum ultrafiltrate volume potentially removable by the hemofilter. More 
precisely, it indicates how much volume of ultrafiltrate fluid can be removed from blood in an hour 
by applying a transmembrane pressure of 1 mmHg. Based on the basic requirements stated before, in 
order to ultrafiltrate a maximum of 2 l per day (corresponding to almost 85 ml/h), and assuming a 
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TMP of 100 mmHg, the minimum ultrafiltration coefficient requested to the hemofilter for the WUF 
is Kuf = 1 ml/h/mmHg.     
It seems intuitive that a high ratio between exchanging surfaces (determined by the whole area of the 
fibers constituting the membrane inside the hemofilter) and volume, maximizes the efficiency of the 
device in terms of removing water, although maintaining restrained the overall size.    
Finally, the priming volume (volume of blood contained in the hemofilter) should not be excessively 
high in order to reduce potential risks of blood loss. 
Based on these requirements, the selection of the appropriate disposable hemofilter has been carried 
out. In particular, the selected hemofilter has been designed by an industrial partner (Medica S. p. A., 
Medolla, Modena, Italy) starting from a commercial device initially targeting pediatric treatments. 
The reduced dimensions of the filter allow a low priming volume and guarantee good ergonomics, 
although the requested permeability parameters are still enough for the WUF. The characteristics of 
the selected hemofilter are summarized in Table 9, while Figure 21 shows the hemofilter. 
Surface area 0.15 m2 
Membrane material  Polysulfone 
Cut-off 50000 Da 
Fiber internal diameter 250 μm 
Fiber external diameter 350 μm 
Fiber thickness 50 μm 
Fiber length 127 mm 
Number of fibers 1700 
Priming volume  10 ml 
Maximum TMP 500 mmHg 
Potting material Polyurethane 
Housing material  Polycarbonate / Copolyester 
Ultrafiltration coefficient 3 ml/h/mmHg 
Table 9. Characteristics of the hemofilter 
 
 
Figure 21. Selected hemofilter for the WUF 
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Tubes 
The tubes (or pipes or lines) of the extracorporeal circuit are the disposable components which come 
directly in contact with blood. Tubes have to be made of hemo-compatible material and have to 
interact with the not disposable components of the device. One important requirement is that these 
tubes must allow a low priming volume (the whole blood volume contained in the extracorporeal 
blood line). Consequently, the inner and outer diameter needs to be selected taking into account these 
aspects.   
The tubes are typically made of polyvinylchloride (PVC), although even other biocompatible 
materials such as silicone or polyurethane rubber (depending on the application) can be applied. The 
cost of this component is generally low, so the reuse is not considered economically viable. In addition 
to the tubes coming in contact with the blood (blood line), there is an additional line leading the 
ultrafiltrate from the exit site of the filter to the tank (ultrafiltrate line): this part of tubes does not 
need to meet strict requirements in terms of hemo-compatibility.  
The bloodline can be divided into: access line and return line.  
The access line is the part of tubing from the patient's vascular access to the hemofilter. It also 
considers the part of tube connecting the actuator for infusion of heparin with the main blood circuit. 
The return line is the line that connects the hemofilter to the patient's vascular access.  
The connections with the hemofilter of access and return lines have to be of luer-lock type. This type 
of connections, regulated by the standard ISO 8637-2 and characterized by threaded components, 
allows a safety block of the joints between the tubes and the hemofilter, preventing potential 
disconnections.  
Based on all these considerations, the dimensions and materials selected for the extracorporeal circuit 
of the WUF are represented by a CAD design in Figure 22. 
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Figure 22. CAD representation of tubes selected for the WUF 
 
Ultrafiltration pump 
The ultrafiltration pump is the pump used to make ultrafiltrate flow. The requirements that a UF pump 
must guarantee in order to be applied in a wearable/portable device are:  
• It should be compact, small, and light  
• It should have a few moving parts in order to assure reliability; 
• It does not need to have biocompatibility characteristics (as in the case of the blood pump) 
but it must be sterile (in case of a slight UF backflow, avoiding any bio-chemical hazard);  
• It should avoid backflow of ultrafiltration liquid, therefore it is necessary to ensure that the 
ultrafiltration pump is occlusive or to use non-return valves; 
• It must ensure adequate flow of ultrafiltration: based on the requirements previously stated, 
the ultrafiltration flow range may vary between 1 and 7 ml/min; 
• It must ensure an accurate control of the set value of flow rate since the excessive or reduced 
removal of plasma water from a patient may have consequences related to physiological 
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hemodynamic instability; there are no precise data in literature on these maximum limits 
allowed for devices like the WUF. However, taking into consideration the standard IEC60601-
2-16, concerning hemodialysis machines for chronic patients (where, however, the applied 
flow rates are much higher and therefore not fully coherent with those of miniaturized 
devices), it should be guaranteed that: 
a) the NET FLUID REMOVAL (weight loss over duration) must be within ± 0.1 l/h 
of the set point, and 
b) the target NET FLUID REMOVAL is to be kept within ± 400 ml at any time during 
the treatment; 
• It should be silent and introduce negligible mechanical vibrations; 
• It should guarantee low energy consumption and high efficiency; 
• It should have a good cost/effectiveness ratio. 
Based on these specific requirements, a wide range of pump typologies has been investigated. Two 
types of pump were found suitable: 
• Diaphragm pumps 
• Peristaltic pumps 
 
Diaphragm or membrane pumps exploit the combination of the reciprocating action of a diaphragm 
and suitable valves to pump the fluid. On the contrary, peristaltic pumps (further described later, for 
the blood pump application) are based on alternating compression and relaxation of a tube to draw 
the fluid into it. Compression and relaxation are imposed by a rotating roller passing along the length 
of tube. The main difference, in terms of applicability, between these two types of pump is related to 
the fact that first ones have to be disposables, since there is direct contact between the fluid and the 
main structure of the pump, while the second ones may not be disposable since the tube is the only 
part contaminated by the ultrafiltrate.  
Since peristaltic pumps are always driven by a rotating motor, they cannot achieve relevant levels of 
miniaturization. A disposable diaphragm MEMS micropump using piezoelectric actuators has then 
be selected (Figure 23). The pump is the mp6 micropump manufactured by Bartels Mikrotechnik. 
The functional principle of the MEMS micropump is based on a piezoelectric diaphragm in 
combination with passive check valves. A piezo ceramic plate mounted on a coated brass membrane 
is deformed when voltage is applied. By the resulting down stroke, liquid (e.g. ultrafiltrate) is being 
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displaced out of the pump chamber below. The check valves on both sides of the pump chamber 
define the direction flow. 
 
 
  
 
 
 
 
 
 
 
 
Figure 23. Selected ultrafiltrate pressure for the WUF 
 
The ultrafiltration flow that the disposable reciprocating membrane pump is able to generate is a 
function of the voltage, shape and frequency of the control signal. Voltage (up to 250Vpp) determines 
the height of the deflection of the piezoelectric actuators while the frequency affects the number of 
deflections. By varying the frequency (range 1 – 300 Hz), together with the shape of the signal (e.g. 
rectangular or sinusoidal waves), it is possible to obtain different flows. A rectangular signal returns 
higher flows (maximum 7 ml/min), while a sinusoidal wave minimizes the pump noise. 
 The characteristics of the pump are summarized in Table 10. 
Maximum pressure 450 mmHg 
Dimensions 30 x 15 x 3.8 mm 
Weight 2 g 
Material in contact with ultrafiltrate Polyphenylsulfone 
Power consumption < 200mW 
Life time  5000 h 
Table 10. Technical characteristics of the selected ultrafiltration pump   
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5.2.2 Off-the-shelf sensors 
Among off-the-shelf sensors there are pressure sensors, the air sensor, the blood leak detector sensor 
and the temperature sensor. 
Pressure sensors 
As it has been stated previously, during the risk management analysis, pressure sensors are 
fundamental components that must guarantee a continuous measurement of the relative pressure 
levels in the circuit in order to avoid any hazardous situation due to blood loss. In particular, pressure 
sensors need to be placed:  
• in the access line (in order to measure the so called "access pressure"): this value is negative 
because the sensor has to be placed upstream of the pump, where there is blood suction, to 
monitor any hazardous situation possibly leading to blood loss in this part of the circuit. The 
pressure acceptable range in adult machines ranges from -500 mmHg to 0 mmHg, depending 
on the clinical condition of the catheter. The monitoring of the access pressure is performed 
to check the clinical situation of the catheter and to detect if access tubes are well connected 
or obstructed. 
• in the prefilter line (where the so called “pre-filter pressure” is measured): this value is positive 
because the sensor has to be placed downstream of the pump (but upstream of the hemofilter). 
The acceptable pressure range in adult machines ranges from 0 mmHg to +500 mmHg. This 
pressure sensor is applied in order to detect if there is any obstruction in the hemofilter due to 
coagulation, clotting or clogging. 
• in the return line (where the "return pressure" is measured): this value is positive because the 
sensor has to be placed downstream of the pump (and downstream of the hemofilter). The 
acceptable pressure range in adult machines ranges from 0 mmHg to +500 mmHg. The 
monitoring of the return pressure is performed to check the clinical situation of the catheter 
and to detect if return tubes are well connected or obstructed. 
• in the ultrafiltrate line (in order to measure the “ultrafiltrate pressure”): this value is positive 
during the first part of the treatment, since the membrane inside the hemofilter is clean and 
not obstructed by phenomena like clotting or clogging. When the pores of the membrane start 
becoming occluded, this pressure first starts decreasing and then becomes negative. The 
acceptable pressure range in adult machines ranges from -500 mmHg to +500 mmHg. This 
pressure sensor is applied in order to detect if there is any obstruction in the hemofilter due to 
clogging inside the pores of the fibers. 
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The use of disposable MEMS devices instead of standard pressure sensors used in hospital machines 
allows to miniaturize the whole system (Figure 24).  
 
Figure 24. Selected pressure sensors for the WUF 
 
The sensors chosen are Argon Standalone DTX Plus™ manufactured by Argon Medical Devices. 
The blood pressure detection system inside the sensor is based on a silicon chip applied on a 
diaphragm, where piezo-resistive elements or extensometers in Wheatstone Bridge configuration are 
placed. The sensor power supply is connected to the bridge to generate an excitation voltage. A 
current meter is also connected to determine the pressure exerted by the fluid. When no voltage is 
applied to the strain gauge, the Wheatstone Bridge is in balance and no electrical current flows 
through the amperemeter. However, when a load exerted by the fluid is applied to the pressure gauge, 
there is a variation in the resistance of the strain gauge, which in turn causes a change in the output 
voltage of the Wheatstone Bridge that is directly proportional to the amount of fluid pressure that 
causes the element bending. The electrical connections of the MEMS are protected from the liquid 
by an elastic silicone gel. This gel provides electrical insulation by preventing any electrical shock 
from the sensor to the patient and vice versa. 
 
Air sensor 
For the WUF, an air bubbles detector must be applied before blood is reinfused into the patient. In 
case of air detection, the control system must immediately stop the pumps in order to avoid any air 
infusion. Different technologies have been proposed in order to detect air in plastic tubes of 
extracorporeal circulations. In particular, they are: 
• Optical sensors 
• Capacitive sensors 
• Ultrasound sensors 
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The earliest air bubbles detectors were optical. They consisted of a light source which triggered a 
photocell situated on the opposite side of the tube. The cell did not react if blood obstructed the light 
path. Anyway, this device was not so sensitive and could not react if the light path was obstructed by 
fibrin deposits on the inner wall of the circuit.  
The capacitive technology is based on the difference in electrical impedance between fluid and air. 
Fundamentally, capacitors whose capacities differ significantly (even 80 times) between fluid and air 
are used. The capacity is measured by plates placed outside the tube. These plates are connected to a 
bridge. The bridge must be carefully balanced giving a zero output, or a set threshold, when only the 
fluid flows through the tube. This method of detection is however subject to errors due to the low 
detection threshold (it is very difficult to detect a bubble of 1mm of diameter determining a variation 
of capacity of about 1 pF), and requires complex and expensive precision electronics. Furthermore, a 
frequent calibration is required. 
The most used MEMS technology for detection of air bubbles is based on ultrasounds (Figure 25). 
  
Figure 25. Selected air sensor for the WUF 
The ultrasonic approach is based on the great difference between acoustic impedance between liquid 
and air. The velocity varies from 331 m/sec in air to 1570 m/sec in blood. Furthermore, it is not 
dependent on the concentration, opacity and color of the fluid. Pulse-type ultrasound sensors detect 
the presence of air or liquid based on the velocity or transit time of the received signal. Ultrasound 
sensors contain integral piezoelectric crystals which utilize high-frequency acoustic energy 
(resonance frequency from 1 to 3 MHz, generally next to 2.25 MHz). The receiver crystal vibrates 
based on ultrasonic vibrations received from the transmitter crystal, and generates an electric signal. 
Following each pulse, the electronics checks whether a return signal is received within a specific 
window of time, which corresponds to the time that the wave takes to pass through the liquid-filled 
tubing. Only signals received within this temporal window indicate that there is fluid and not air. 
Signals which have been interrupted by air will not be received within this window. 
Based on its advantages the technology adopted in the WUF is the ultrasonic one. The selected non-
disposable device, the Sonocheck ABD-07 manufactured by Sonotec, has a U-shaped body able to 
accommodate the tube where blood flows: in the opposing arms of the U, the two piezoelectric 
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transducers (transmitter and receiver) are positioned. Furthermore, the air sensor device generates a 
control signal that can be employed to check whether the tube is correctly positioned in the device. 
The amplitude of this signal is at a low level if the tube is not positioned in the sensor, at a high level 
if the tube is properly positioned and fluid is flowing, at a medium level if the tube is properly 
positioned but air is detected. 
The standard IEC60601-2-16 declares that the maximum allowed air infusion limit per unit of time 
is 0.03 ml/(kg min), while as bolus infusion, the limit is 0.1 ml/kg. The air sensor has to be inserted 
in the return line, possibly in a position far from the blood reinfusion to the patient in order to 
preventively avoid air infusion. Typically, an air removal system is present in the extracorporeal 
circuit and is placed immediately before the air sensor. It will be proved in Section 5.3.2 that it makes 
sense not to introduce such a system in the designed portable device. 
Blood leak detector sensor 
Another important condition to monitor during the treatment is to test if the fibers inside the 
hemofilter are not broken, which may lead to possible blood losses from the blood compartment to 
the ultrafiltrate compartment. This can be caused by an excessive pressure exerted on the fibers. With 
reference to the standard IEC60601-2-16, the maximum acceptable blood flow lost must be less than 
0.35 ml/min, considering a hematocrit value of 32%. In order to immediately detect this hazardous 
situation, a sensor can be placed directly in this part of the extracorporeal circuit. This sensor is called 
Blood Leak Detector (BLD). The leading technology is the optical one. 
The selected non-disposable BLD is an optical sensor (Figure 26). It is based on the optical detection 
of the light that passes through the ultrafiltrate tube. A decrease in the amount of light passing through 
the tube indicates the presence of hemoglobin in the ultrafiltrate and therefore, most likely, a break 
in the filter membrane. The BLD sensor is made of:  
• a light source (light emitting diode - LED) that generates, through an optical path, a beam 
having a wavelength ranging between 800 nm and 930 nm (infrared) 
• a light detector (photodiode) which receives the beam,  
• a case, made of plastic, with a slot suitable to fit a tube between the light source and the light 
detector. 
The light absorption of the oxygenated and non-hydrogenated hemoglobin is almost in a range of 
wavelengths of between 800 nm and 930 nm. The narrow emission spectrum, together with the use 
of an enclosed housing, allows the BLD not to be substantially affected by environmental light. As 
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for the output, the sensor generates a voltage that is proportional to the intensity of the light energy 
coming from the LED and hitting the photodiode: if blood flows into the optical path, the light 
intensity decreases and, if it is lower than a set threshold, the hazardous situation can be detected. 
 
Figure 26. Selected blood leak detector sensor for the WUF 
 
Temperature sensor 
In order to detect if the temperature in the extracorporeal circuit is too low (possibly leading to 
hypothermia) or too high (possibly leading to hyperthermia), a temperature sensor has been adopted. 
The sensor has been placed close to the pre-filter line. The selected analog temperature sensor is the 
module LM35D (Figure 27). The presence of a temperature sensor also allows implementing a 
cooling strategy for the WUF by simply managing a fan. Several miniaturized, silent, energy efficient 
and cheap fans can be found in electronics catalogs, being extensively used in pc’s and notebooks. 
For this reason, the fan chosen is not shown here. 
 
 
Figure 27. Selected temperature sensor for the WUF 
 
The temperature sensor has a measuring range between 0 and 100°C. The voltage supply is between 
4 and 30 V, output voltage between 0 V and 6 V.  
 
5.2.3 Off-the-shelf microcontrollers 
In order to identify and select the most suitable hardware components for the control system, the main 
technical requirements have been initially identified based on: 
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- clinical specifications and functionalities expected for the WUF, as indicated by the medical 
staff of the hospital; 
- analysis and comparison of off-the-shelf control systems applied for other electro-medical 
devices used for hemodialysis and ultrafiltration; 
- indications deriving from the standards regulating the control system requirements for electro-
medical devices. 
The current standard IEC 60601-1 concerning electro-medical devices expressly declares that the 
control system of such devices must be accomplished with a redundant logic. It means that the overall 
system must be designed considering the use of two microcontrollers working in parallel: if a 
malfunction of the main controller may potentially cause a hazardous situation and, consequently, a 
risk for the patient, the use of the second one allows to immediately detect the problem, switching the 
device into a safe mode. This requirement represents a specific commitment in the design of the WUF, 
although the use of two controllers working in parallel determines an increase in size, higher power 
consumption and higher complexity of the software and control logic that has to be implemented. All 
these drawbacks could be effectively addressed by designing and developing a customized control 
architecture, which is however beyond the scope of this project.  
In order to find an optimal solution able to combine the above-mentioned requirements with the need 
for providing adequate flexibility to the WUF controller (in order to make it usable even in changing 
working conditions or improved future versions of the prototype), it has been decided to design the 
control electronics just adopting commercially available programmable hardware platforms for 
physical computing. Indeed, such solutions are certainly suitable for a preliminary project, but may 
present some limitations in an industrialized device. In that case, if necessary, customized boards 
replicating the same control logic can be developed straightforwardly. The aforementioned 
commercially available platforms usually integrate a microcontroller on which a dedicated 
development environment is pre-installed and can be connected directly, or through suitable 
conditioning modules to sensors and actuators. Software programming is often simplified thanks to 
the use of high level standard languages. Specific development kits further simplify debugging and 
testing software programs. Different off-the-shelf integrated programmable hardware platforms have 
been evaluated and compared (some examples are Arduino, Raspberry PI, Beagleboard, Freescale, 
Texas Instruments MSP430), in order to identify the ones guarantying adequate standards of 
reliability and scalability. Clearly, some of the above listed platforms are just microcontrollers (e.g. 
Arduino) while other ones are microcomputers (e.g. Raspberry). The formers have improved 
capabilities to manage sensors and actuators by numerous digital and analog input and output (I/O) 
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ports, the latter usually give the possibility to generate more complex GUI’s (graphical user 
interfaces) and provide more computational power but usually have a very limited number of I/O 
ports.  
One relevant aspect that has been taken into account in the selection of the hardware platforms was 
the possibility to easily integrate them into an electronic circuit board to which sensors, actuators and 
drivers would be connected. 
Based on the peculiar features of the WUF, it has been decided to use separate hardware platforms to 
control all the devices involved in the extracorporeal ultrafiltration therapy and to manage the GUI 
and data logging. In particular: 
• the hardware platforms that monitor the ultrafiltration process must ensure real time 
operations and must be able to handle serious or anomalous situations requiring an immediate 
suspension of the treatment in order to avoid any risk for the patient; two identical but 
independent microcontrollers working redundantly are used to this purpose; 
• that hardware platform managing the GUI, the initial set-up of the treatment (by a physician 
or an experienced nurse), remote monitoring during therapy and data logging locally or 
through the internet is a single microcontroller. No redundant control is required to this 
purpose. 
Therefore, the WUF control architecture is based on 2 microcontrollers and 1 microprocessor that 
need to work independently but synergistically, in order to coordinate the whole machine cycle of the 
WUF. The comparison with other electro-medical devices has shown that such an architecture is used 
frequently since it guarantees patients’ safety without excessively complicating the device 
electronics.  
Namely, the microcontrollers used are those belonging to the Arduino Mega platform (Figure 28). In 
particular, two Arduino Mega kits have to work in parallel in order to implement a redundant logic: 
the first one (the so-called control system) controls the ultrafiltration process of the WUF, the second 
one (the so-called protective system) performs appropriate redundant control routines. Arduino Mega 
consists of a stackable board of dimensions 102 x 53 mm, which is based on a 16 MHz ATMEL 
ATmega2560 CPU with 256 kb of memory. It has 54 digital I/O ports, 14 of which provide PWM 
outputs, and 16 analog inputs. The power consumption of each board is very low (estimated in a range 
between 100 and 200 mW in working conditions) in relation to the skills of computing and data 
processing that the development kit is able to offer.  
66 
 
  
Figure 28. Arduino Mega platform: the selected off-the-shelf microcontroller for the control of the ultrafiltration 
process of the WUF 
 
As for the management of the GUI, the initial set-up, monitoring and data logging, an embedded 
microcomputer with an extremely reduced footprint has been adopted. Specifically, the single board 
computer Raspberry PI 3 model B (Figure 29), based on ARM processor, has been selected. The 
board, of dimensions 85 x 56 x 17mm, is equipped with a CPU 7 1.2GHz Broadcom BCM2387, 4 x 
USB 2.0 ports, 40 pin extended GPIO (Serial, I2C, SPI), Micro SD slot for the operating system 
and data storage and 1Gb of RAM memory. It hosts a Linux-based operating systems. 
  
Figure 29. Raspberry PI 3 model B platform: the selected off-the-shelf microcomputer for the management of GUI 
and data logging of the WUF 
 
During the therapy, the interface between the device and the patient is based on a LCD touch screen 
monitor Nextion LCD (Figure 30) through which the microcontrollers can communicate warning 
messages or emergency situations that can be easily resolved independently by the patient. Examples 
of such situations are a temperature out of the prescribed range, low battery power or a full 
ultrafitration tank. 
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Figure 30. Selected LCD monitor for the WUF 
The LCD screen has been used also to communicate the current state of the device, so if the therapy 
is in progress, whether in start-up mode or even when the therapy is over. During the therapy, the 
monitor provides real-time information on the battery charge status and the quantity of ultrafiltrate 
removed. The touch screen also allows to pause or permanently stop the treatment. 
5.2.4 Electric and electronic devices (boards and sensor conditioning system) 
 
The relevant number of off-the-shelf electric and electronic components of the WUF, combined with 
a few customized ones which will be discussed later, has made it necessary to develop customized 
electronic boards simplifying the wiring of all such components and the conditioning of sensor 
signals. The development of the electronic boards has been carried out by a team of engineers 
involved in the RAP project given the peculiar expertise necessary for designing and commissioning 
printed circuit boards (PCBs). 
In particular, the set of PCBs has been specifically designed and realized in order to integrate both 
disposables and non-disposable components needing signal conditioning (sensors) or driver circuits 
(pumps and electro-mechanical clamp). The design of the electric and electronic circuitry has been 
conceptualized and realized taking into account that: 
• the miniaturization and compactness of PCBs are important requirements for the overall 
design of the WUF; 
• disposable components needing a conditioning circuitry or driver circuit have to be easily 
connected with the relative PCBs; 
• connections of electric cables with the PCBs should be practical and functional. 
Based on these considerations, four main PCBs have been designed and realized. They are: 
• the main PCB where the two microcontrollers have also been integrated; 
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• a power board for driving the motors of the blood pump, the heparin pump, and the clamp; 
• a signal condition PCB for pressure sensors; 
• a PCB for the driver of the UF pump. 
The main PCB, with the main components and conductive tracks, is represented in Figure 31. 
 
 
Figure 31. General scheme of the main PCB of the WUF 
 
 
The power board is represented in Figure 32. 
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Figure 32. General scheme of the power board of the WUF 
 
As previously stated, disposable components like pressure sensors and the ultrafiltration pump need 
to be easily connected to dedicated PCBs. The PCB for the conditioning of the electric signals from 
pressure sensors is shown in Figure 33, while the one driving the UF pump is shown in Figure 34. 
 
 
Figure 33. PCB for signal condition of pressure sensors 
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Figure 34. PCB for driving the UF pump 
 
 
 
 
 
5.3 Critical components: requirements, selection and design 
As stated, the critical components needed a specific investigation. They are: 
• Blood pump 
• Air removal system 
• Heparin infusion system 
• Electro-mechanical clamp 
• Ultrafiltrate collection and volume measurement system 
 
5.3.1 Blood pump 
The blood pump is the core of the system. It allows the circulation of blood in the extracorporeal 
circuit. The requirements that the blood pump must meet are:  
• not to exert excessive mechanical stress possibly leading to rupture of red blood cells: it means 
that it must ensure a reduced hemolysis and reduced cytotoxicity. This requirement, that can be 
stated as hemo-compatibility, is probably the most important; 
• miniaturization, compactness and lightness;  
• minimal contact area and duration of contact between blood and moving parts: these factors are 
both relevant in the determination of the hemolysis rate; 
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• to ensure an adequate blood flow: the chosen value for the WUF is 50 ml/min, in order to perform 
an extracorporeal ultrafiltration treatment extended throughout the day. This value guarantees an 
adequate shear rate value along the membranes through which blood flows, in order to reduce 
the contact time between blood and thrombogenic material and consequently to reduce 
coagulating phenomena. Furthermore, the chosen value is coherent with the desired filtration 
fraction, that is the percentage ratio between the ultrafiltration flow and the blood flow; from 
literature, such a relationship cannot exceed a value of approximately 30%, otherwise it is easier 
to promote blood coagulation within the filter; 
• not to induce blood overheating; 
• not to cause too much noise and relevant mechanical vibrations; 
• to assure low energy consumption; 
• to have a good cost/effectiveness ratio. 
Based on these requirements, the most suitable available technologies have been identified. Generally 
speaking, the blood pumps that can be used in an ultrafiltration device can be divided into positive 
displacement pumps and dynamic pumps [47]. 
A dynamic pump produces a head and a flow by increasing the velocity of the liquid through the 
machine with the help of the rotating vane impeller. None of the dynamic pumps can have a separate 
case such as flexible tubing because all the dynamic pumps need a connection between the outside 
and the inside of the case of fluid (e.g. a shaft that provides centrifugal force). The direct contact with 
the blood and the pump moving parts could lead to possible infection and blood clotting problems. 
Consequently, dynamic pumps can only be employed if they are introduced in the design as 
disposable devices. These pumps have the advantage that they do not need valves, that may lead to 
hemolysis; on the contrary, the flow and the efficiency of these pumps usually decrease when the 
output pressure increases. Often, these pumps need to be primed, that means to be initially filled with 
fluid to start operating.  
The main types of dynamic pumps are: 
• Centrifugal pumps (Figure 35): these pumps are based on the effect of centrifugal force on a 
fluid; 
• Axial pumps. 
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Figure 35. Schematic example of a centrifugal pump  
 
Positive displacement pumps are constant flow devices and make blood move by trapping a fixed 
amount of blood and forcing (displacing) that trapped volume into a discharge pipe or discharge 
system. Two main kinds of forces push the fluid in pumps. One is the translational force, which is 
applied in the translational direction of the flow, and the other is the normal force, which is applied 
to the normal direction of the flow. All positive displacement pumps operate by combining these two 
forces.  
The main feature of these pumps is that the flow rate is constant for each operating cycle and it does 
not depend on the discharge pressure, but only on the number of cycles performed in the unit of time.  
Positive displacement pumps can be further classified according to the actuator used to move the 
fluid. They can be defined as: 
• rotary: when the actuator is coupled with a rotating motor; 
• alternatives: when the actuator is moved with an alternate motion. 
The main types of rotary pumps are gear pumps, lobe pumps and peristaltic pumps. Peristaltic pumps 
are the most employed in the medical field (Figure 36): they are based on alternating compression 
and relaxation of the tube drawing the fluid into it. A rotating roller passes along the length of the 
tube totally compressing it and creating a seal between suction and discharge side of the pump. Upon 
restitution of the tube a strong vacuum is formed drawing the fluid into the pump. The fluid to be 
pumped does not come into contact with any moving parts and is totally contained within the extruded 
tube. 
 
 
Figure 36. Schematic example of a peristaltic pump 
 
The main types of alternative pump are: 
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• plunger or piston pumps: in which the volume variation is obtained by alternating sliding of 
a piston in a cylinder; 
• diaphragm or membrane pumps: combining the reciprocating action of a diaphragm and 
suitable valves on either side of the diaphragm to pump the fluid.  
 
Among positive displacement pumps and dynamic pumps, the two types of pumps most employed in 
extracorporeal blood circulation devices are centrifugal pumps and peristaltic pumps. 
As previously stressed centrifugal pumps need to be disposable and theoretically their overall cost 
can be higher. Furthermore, when considering a possible application to the WUF, since the surface 
coming in contact with blood is quite wide and the blood flow desired relatively low (50 ml/min), 
risks related to blood clotting are high. Nevertheless, this type of pump guarantees continuous flows 
(no pulse, thus less localized shear stress), and good energy efficiency, and have therefore be 
considered a possible option. 
Peristaltic pumps are the ones currently used in hospital dialysis machines. They have the big 
advantage to guarantee an indirect contact between the rotor and blood (the physical interface is the 
tube). On the other hand, they can be bulky (mainly as a consequence of the motor and gearbox size) 
and are less energy efficient.  
After an extensive research of possible candidates within these two categories of pumps, and 
especially among the peristaltic ones, the following off-the shelf centrifugal and peristaltic pumps 
have been selected (Figure 37): 
• Peristaltic pump Welco WPX1;  
• Centrifugal pump RS M400-S180. 
 
Figure 37. Preliminary selected peristaltic and centrifugal pumps for the WUF 
 
The main characteristics of these pumps are summarized in Table 11.  
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 Welco WPX1 RS M400-S180 
Pump type Peristaltic Centrifugal 
Dimensions 46 x 49 x 96 mm L=41x 26 x 25 mm  
Weight 132 g 33 g 
Voltage 8 to 24 Vdc 12 Vdc 
Power consumption 7,2 W 6 W 
Max flow 175 ml/min 2800 ml/min 
Table 11. Main technical characteristics of selected blood pumps 
 
 
Considering the initial requirements reported at the beginning of this paragraph, the most important 
characteristic that these pumps must comply with is the hemo-compatibility. No data or analyses are 
made available by the pump manufacturers, in this sense these components are critical and deserve a 
specific investigation, which has been carried out in collaboration with the clinicians of the hospital. 
Hemo-compatibility has been evaluated in terms of hemolysis and cytotoxicity. Hemolysis is the 
phenomenon of red blood cell rupture due to mechanical stress, resulting in the release of free 
hemoglobin, the iron-containing oxygen-transport metalloprotein in the red blood cells, into 
extracellular space. Cytotoxicity assesses the potential harmful effect on blood cells that come into 
direct contact with the materials of the pumps.  
Since there are no specific standards complying with the methodology for the evaluation of the 
hemolysis in specific circulators for hemodialysis, the ASTM F1841-97 standard has been 
considered. This standard deals with in vitro testing methods for the evaluation of hemolysis in 
continuous-flow blood pumps, specifically suitable for extracorporeal oxygenation devices. 
Hemolysis results obtained using the pump of a continuous renal replacement therapy standard 
machine have also been collected and considered a reasonable benchmark, since the pump employed 
in such a machine has already obtained the CE mark and hence its hemolytic values should be within 
a range of safety. 
For each of the three experiments carried out, 530 ml of blood from healthy donors were used. The 
initial hematocrit level was between 34% and 38%. During the whole experiment, blood temperature 
was kept constant at 36°C by a magnetic stirrer with a heating plate. According to the standard ASTM 
F1841-97, the treatment duration has been 6 hours, sampling at every hour. The setup of the 
experiment for each pump is represented in Figure 38. 
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Figure 38. Set up of the in vitro experiment for the three pumps (benchmark pump, centrifugal pump and peristaltic 
pump). 
 
Free hemoglobin concentration has been measured for each sample. This measurement has been 
carried out using a "point of care" system (Hemocue, Angelholm, Sweden). A parallel analysis of the 
same samples was also carried out in the Central LAB of the Vicenza hospital, where a 
spectrophotometric method has been used to determine discrete ranging levels of free hemoglobin 
concentrations. For each sample, the measurements obtained with the two methodologies matched. 
The value of hemolysis was calculated through a normalized hemolysis index: 
 
𝑁. 𝐼. 𝐻 =  ∆𝑓𝑟𝑒𝑒𝐻𝐵 ∙ 𝑉 ∙
100−𝐻𝐶𝑇
100
 ∙ 
100
𝑄∙𝑡
 
 
where N.I.H. is expressed in g/100l, ΔfreeHB (g/l) represents the difference in free hemoglobin 
concentration between the sampling time point considered and the baseline, V (l) is the volume of the 
circuit, HCT the hematocrit, Q (ml/min) is the blood flow rate, t (min) is the time interval. 
The test has been carried out at a blood flow of 50 ml/min for each pump. 
Results are shown in the two graphs of Figure 39 and in Tables 12 and 13. 
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Figure 39. Results of in vitro hemolysis tests. The subplots a and b represent the normalized index of hemolysis 
(N.I.H.) and hemoglobin concentration respectively. 
 
 
 
N.I.H. (g/100 l) 
Test duration (min) 
0 60 120 180 240 300 360 
Benchmark pump  1.08 0.92 0.92 0.82 0.85 0.89 
Peristaltic pump  1.11 1.29 0.61 0.48 0.64 0.62 
Centrifugal pump  1.10 1.78 1.87 1.67 1.36 1.71 
Table 12. Results of Normalized Index of Hemolysis using the 3 pumps 
 
Free hemoglobin 
concentration 
(g/l) 
Test duration (min) 
0 60 120 180 240 300 360 
Benchmark pump 0.00 0.01 0.02 0.03 0.03 0.04 0.05 
Peristaltic pump 0.00 0.01 0.02 0.02 0.02 0.03 0.04 
Centrifugal pump 0.00 0.01 0.03 0.05 0.07 0.07 0.10 
Table 13. Results of free hemoglobin concentration using the 3 pumps 
 
a 
b
a 
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N.I.H. and free hemoglobin concentration values of the selected miniaturized peristaltic pump (in 
red) are comparable to the ones of the benchmark pump (in blue), while the centrifugal pump (in 
green), after two hours of experiment, determined values approximately twice higher than the 
benchmark pump. 
These results have been confirmed also by a basic colorimetric evaluation of the samples referred to 
the three pumps (Figure 40). The higher presence of hemoglobin in the samples taken during the in 
vitro test performed with the centrifugal pump with respect to the ones performed with the other two 
peristaltic pumps is evident.   
 
 
 
 
 
 
 
 
Figure 40. Colorimetric evaluation of hemoglobin concentration in samples taken during tests with the benchmark 
pump (a), peristaltic pump (b) and centrifugal pump (c). 
 
As for the cytotoxicity test, blood samples were taken after 3 and 6 hours from the start of the test 
and then centrifuged to obtain plasma. A particular cell line of blood, U937-line monocytes, was 
incubated for 48 hours with the plasma samples. At the end of the 48 hours, differences in viability 
and necrosis (cell death for non-natural causes) of the incubated monocytes were evaluated through 
a flow cytometer. 
The results of the induced cytotoxicity test are shown in the following charts. In the histograms 
(Figure 41), normalized Δ% values with respect to baseline are represented. 
 
a b
a 
c 
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Figure 41. Monocytes viability and necrosis after 48 h of incubation with blood coming in contact with the 3 pumps 
 
 
To properly interpret the results, it is necessary to consider that variations below 5% are not 
significant. From the results obtained after 48 hours of incubation, it is possible to notice that the cell 
behavior is homogeneous and within a low variability between the three considered pumps (values 
between ± 2%). We can therefore conclude that the three considered pumps induce negligible 
cytotoxicity. 
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In conclusion, these experiments revealed that the centrifugal pump, despite generating acceptable 
cytotoxicity values, induces hemolysis levels which were considered too high and suggested to 
discard it for the WUF application. The peristaltic pump has been selected for the WUF prototype. 
 
5.3.2 Air removal system 
Air infusion into the circuit is considered one of the most dangerous hazard situations for patients 
during extracorporeal blood purification therapies performed with continuous renal replacement 
therapy and ultrafiltration machines.  
According to standard IEC 60601-2-16 (2012), safety conditions are guaranteed if: 
• continuous air infusion is less than 0.03 ml/(kg∙min); 
• infusion of air bolus is less than 0.1 ml/kg. 
For a patient weighing 50 kg, the average volume and flow that can be infused in order to be within 
the safety limits set by the standards are respectively: 
• Continuous infusion of air < 1.5 ml/min; 
• infusion of air bolus is less than 5 ml. 
Currently, the risk of embolism due to air infusion into the patient’s circulatory systems is avoided 
by an air removal chamber placed upstream the return vascular access. However, air bubble chambers 
induce blood/air interface and stagnation of blood, often leading to clotting and, consequently, to risk 
of blood loss from the patient. In literature, there are lacks of specific studies and data describing in 
detail the causes of air infusion and the severity of such events. A better understanding of the 
phenomenon could however stimulate the design and development of alternative bubble removal 
systems overcoming the limitations of air removal chambers and opening new perspectives in the 
field of portable/wearable devices for extracorporeal renal replacement therapies.  
In standard hemodialysis machines, the air removal system is a disposable chamber, integrated in the 
disposable extracorporeal circuit, which carries out air removal by gravity effect. This system cannot 
be applied in the WUF because the verticality of the chamber cannot be always ensured. Since there 
is no study evaluating how severe this problem is, an investigation has been carried out in the hospital. 
The aim was to experimentally evaluate the air infused and the prevalence of the possible causes of 
air infusion during a standard therapy performed in hospital.  
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Seven representative extracorporeal treatments performed on critically ill patients in the Intensive 
Care Unit of the hospital, have been investigated. On average, the treatment duration was of 24 hours. 
The modality was continuous veno-venous hemofiltration (CVVH) in pre-dilution mode. The therapy 
is similar to extracorporeal ultrafiltration. The representative scheme of a CVVH modality is shown 
in Figure 42: contrary to extracorporeal ultrafiltration modality, it provides an infusion of 
physiological solution (purple line) in order to replace the plasma water removed by ultrafiltration. 
The infusion can be carried out before (pre-infusion) or after (post infusion) the hemofilter.  
 
Figure 42. Scheme of Continuous Veno-Venous hemofiltration (CVVH) 
 
Blood flow rate (206 ml/min ± 13.4ml/min) and infusion flow rate (2900 ml/h ± 741.6) were variable 
based on clinical prescription. An external ultrasonic air bubble detector sensor identical to the one 
selected for the WUF and described previously, has been placed immediately upstream the air 
removal chamber in the return line (Figure 43). Digital data acquisition and processing were 
performed through the platform NI Compact DAQ and a dedicated software program written using 
NI Labview® 10.0.1. The treatment data logs have been collected from the CRRT machine at the end 
of each session in order to correlate the air infusion events detected by the sensor with the phases of 
the therapy session. 
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Figure 43. Experimental set up of the experiment: an air sensor has been placed immediately before the air removal 
system in a standard machine for extracorporeal therapies 
In general, during the investigated extracorporeal sessions, air presence inside pipes was quite 
infrequent and strictly related to specific and temporary events (initial priming step, incomplete 
priming, bag change, vascular access malfunctions). The total infusion of air, excluding the priming 
phase, was on average 0.001% of the total volume of treated blood, so completely negligible. In 5 out 
of the 7 treatments, no air has been detected during the whole session. Figure 44 shows the number 
and duration of air events recorded during the worst-case session, i.e. the session when the maximum 
number of events was registered. Most of the air presence results enclosed to the priming step (Figure 
44-a): this is obvious, since it is the aim of the priming procedure removing air from the circuit. 
During the real treatment, in normal conditions, air presence is detected in conjunction with particular 
events. Figure 44-b represents the number and duration of events of air detection during the treatment 
in which the maximum number of events has been measured.  
 
Figure 44. Duration of air events during priming (a) and treatment (b) recorded during the treatment in which the 
maximum number of events has been registered. 
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The peak visible in Figure 44-b represents air detection consequent to an event of infusion bag change 
procedure. This event, in an extracorporeal ultrafiltration therapy, does not have to be performed and 
consequently, events of air infusion due to this cause are inherently avoided. Table 14 summarizes 
the total number of events that were associated to air detection during all the seven real treatments 
(excluding the priming steps).  
Cause of air infusion Number of events % over total number of events 
Incomplete priming 3 22% 
Bag change 7 50% 
Catheter mispositioning 2 14% 
Other causes 2 14% 
Table 14. Overall prevalence of detected causes of air infusion during treatment 
It can be noticed that half of the events causing air inflation inside the circuit is due to the bag change 
procedures. However, in absence of peculiar events, air presence can be considered negligible. 
Furthermore, the air infusion flow, estimated in 2.9 ml/treatment in the worst case, was much lower 
than the safety limits specified in the standard IEC 60601-2-16. Based on these experimental data 
collected during seven distinct CVVH treatments, it is possible to conclude that the total volume of 
air inflation during an ultrafiltration treatment is generally low.  
Finally, these results suggest that the risk related to eliminating air removal systems in 
portable/wearable devices is not as high as usually assumed, especially in those devices where direct 
infusion of physiological solutions into the circuit are not applied.  
Consequently, no specific device for eliminating air has been designed for the WUF: in case excessive 
air was detected inside the extracorporeal circuit, an electromechanical safety clamp would close the 
circuit and stop air bubbles before they are infused into the patient. The experimental results discussed 
above prove that this should be a rather infrequent event. 
These results have been published in the posters session of the Congress of the European Society for 
Artificial Organs (ESAO) 2016, in Warsaw [48].  
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5.3.3 Heparin infusion system 
In general, blood extracorporeal treatments are made possible thanks to the anticoagulation therapy 
directly administered into the circuit. If blood comes in contact with non-hemocompatible surfaces 
of the circuit, the coagulation cascade starts soon, leading to formation of clots inside the circuit 
(especially in the hemofilter) and with the potential risk of losing patient’s blood of the patient. 
Two main types of anticoagulation therapies can be administered during a blood extracorporeal 
treatment: the systemic and the regional ones. Nowadays, the regional anticoagulation therapy, 
performed with citrate, prevents the coagulation of blood by chelating calcium directly in the circuit 
and theoretically no infusion of anticoagulant drugs into the patient is determined. However, the 
application of the regional anticoagulation therapy with citrate in a wearable system is not easy to 
make, because the continuous infusion of relatively high flows of citrate (between 500 to 2000 ml/h) 
requires big reservoirs and two further pumps, one for citrate itself and one for the replacement of 
calcium.   
The use of heparin as an anticoagulation drug seems to fit better the requirements for the WUF. Low 
molecular weight heparin can be infused as bolus directly into the circuit immediately after the start 
of the therapy. However, a slow but continuous infusion of unfractionated heparin diluted with 
physiological solution during the whole 24-hours-treatment allows maintaining anti-coagulated the 
blood for a longer period. It has therefore been considered necessary to adopt a system able to 
automatically perform a continuous infusion of such anticoagulant.  
The quantity of heparin to be infused during an extracorporeal blood ultrafiltration therapy depends 
on the total blood volume of the patient and thus, on his weight. However, considering an average 
clinical prescription, almost 1000 International Units (U.I.) of unfractionated heparin need to be 
continuously infused every hour into the circuit immediately before the hemofilter. Usually, a solution 
consisting of 25000 U.I. (5 ml) of heparin diluted in 45 ml of physiological solution is created, in 
order to avoid excessive infusion of the anticoagulant drug into the patient in case of low precision 
of the infusing systems. Based on these considerations, the flow range that a heparin infusion system 
should assure in the WUF is between 0 and 2 ml/h (steps of 0.5 ml/h). A high accuracy would be 
needed. Moreover, if the treatment is intended to be performed for 24 hours, a reservoir/tank of at 
least 50 ml would be necessary. 
Standard infusion pumps used in hospital machines are based on stepper or DC motors that drive the 
piston of a syringe to move the heparin plunger forward. These systems (Figure 45) cannot be adopted 
in the WUF, since they are massive, bulky and difficult to interface with the device controller.  
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Figure 45. Example of massive and bulky heparin infusion system adopted in standard hospital machines 
 
Consequently, a dedicated system for continuous heparin infusion, equipped with a sensor detecting 
when the heparin tank is empty, has been conceived, designed and prototyped. It is based on the 
application of a micro-peristaltic pump able to infuse the drug in a range between 0 and 2 ml/h: such 
a design has allowed achieving a very satisfactory level of miniaturization and lightness. Since this 
system is being patented, no further details can be provided in this paragraph. 
 
5.3.4 Electro-mechanical clamp 
When a hazardous situation is detected in the blood extracorporeal circuit, it should lead to an 
immediate occlusion of the extracorporeal blood circulation. In devices for blood extracorporeal 
circulation used in hospitals, this task is performed by an automatic pinch valve, usually referred to 
as “clamp”. A clamp must be capable of occluding the disposable circuit through which blood flows, 
thereby isolating the problem and significantly reducing direct and indirect risk to patients. 
Furthermore, a clamp should operate normally closed, i.e. it should automatically close the circuit 
whenever no actuation power is available, in order to cope with possible power supply or actuator 
failures. Commercially available safety clamps are usually unsuitable to portable/wearable devices 
being large, heavy and high-power consuming, additionally, their not negligible power losses 
generally lead to high operation temperatures. 
Within the PhD project, two designs have been developed. Since at the beginning of the project the 
blood pump was still to be chosen, the requirement was to occlude both access and return tubes in 
case of selection of a centrifugal pump. A first electro-clamp prototype has been therefore developed 
to satisfy such a strict design requirement embedding a high safety margin. Indeed, the requiring 
pinching force to be applied was higher with respect to the one necessary to occlude only the return 
tube as required whenever an occlusive peristaltic pump is adopted. 
Since the final design of the WUF includes a peristaltic pump, a second clamp prototype has been 
developed with a different architecture, that is more compact than the first one. The second prototype 
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is intended to be patented, and therefore the design of just the first electromechanical clamp will be 
described. 
All the design specifications to be met by the clamp must ensure the essential goal of achieving 
maximum safety to avoid any possible hazardous situation. The correct operation of the device is the 
normally closed one. This feature is commonly achieved using a spring preload, which can be 
counteracted by an electric actuator. Since the clamp should not get in contact with blood, the flow is 
regulated by pinching the tube into which blood flows. The analysis of the commercially available 
solutions has highlighted that a clamp to be used with 4.2 mm-diameter PVC tube requires at least 
4.2 W to keep blood flowing. Such a power consumption is unsuitable for a wearable battery-operated 
device. Indeed, an ultrafiltration treatment usually lasts up to 24 hours, thus a 100 Wh battery capacity 
would be required just to power the safety clamp. This power capacity implies using batteries 
weighting between 500 g and 1 kg, according to the average power density of off-the-shelf lithium-
ion batteries [49]. Both the weight and the generated heat are too high to provide a comfortable 
solution. To reduce both the battery weight and heat generation, the maximum power consumption is 
imposed to be lower than 1 W as a design specification to be met in the present project. 
Preliminary tests have shown that the chosen 4.2 mm-diameter tube requires a maximum pinch force 
approximately equal to 25 N in the typical range of tube materials and dimensions. By choosing a 
safety factor equal to 2, the force that need to be exerted by the clamp should be at least equal to 50 
N. This choice might allow adapting the clamp to a configuration in which both the inlet and outlet 
tubes need to be pinched by a single device. The clamping force should be provided by the spring 
preload alone, since the desired tube occlusion should be performed without the aid of the actuator. 
Such a force must be provided for a clamp displacement that is at least equal to the size of the internal 
tube diameter, which is 2.6 mm in the system under investigation. For safety requirements, the 
maximum blood flow considered for the design of the clamp has been considered equal to 70 ml/min 
and not 50 ml/min as previously described. In such a condition, the linear speed of the blood is equal 
to 0.224 m/s. Thus, blood flow should be stopped within 0.67 s if the distance between the last safety 
sensor and the patient’s vascular access is at least equal to 150 mm, as chosen in the layout of the 
system. Finally, if a safety factor of 10 is used in this situation to improve safety, the design target is 
to ensure a complete occlusion with 67 ms from the detection of the fault. 
In accordance with these specifications, the prototype of the clamp has been designed. It is based on 
a multi-loop articulated mechanism.  
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Figure 46. Kinematic scheme and external forces exerted on the clamp mechanism 
 
 
According to the kinematic scheme in Figure 46, the mechanism is defined as the cascade of two 
four-bar linkages. The coupling between the two four-bar mechanisms is provided by the ternary link 
3. The choice of an articulated design is motivated by the need to achieve high force advantage, thus 
requiring a reduced size actuator. A careful design of articulated mechanisms, moreover, allows to 
reduce to a minimum the overall size of the device. The preliminary CAD design, shown in Figure 
47, shows that the mechanism can be fit almost entirely within the footprint of the actuator. The 
design avoids the use of prismatic joints to comply with the manufacturing limitations imposed by 
the rapid-prototyping machine used to produce a working sample of the device. 
 
Figure 47. CAD design of the clamp, open (a) and closed (b) configurations 
 
Figure 47 shows the mechanism in the closed configuration. The spring is hosted between the ground 
link (shown in light blue) and the electric motor. According to the kinematic scheme of Fig 40, the 
motor provides torque 𝑇𝑚 about joint O and drives link 1 directly. No reduction gear has been 
introduced in the design to reduce the number of elements of the mechanism and to ensure back-
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drivability of the mechanism. Back-drivability is essential for the correct operation of the device and 
is the capability of the force exerted by the spring to overcome the motor detent torque and the 
resistant force opposed by the tube and promptly move the mechanism in case of need. The fixed end 
of the spring is located at point N, while the other end is connected to link 5 at point M. The choice 
of the spring ad its location must ensure an adequate magnitude of the force 𝑓𝐶𝐿𝐴𝑀𝑃 exerted on the 
tube where blood flows. Tube pinching is provided by a small size metal pin located at point C on 
link 5. Spring preload is, during normal operation, counteracted by the counter-clockwise torque 
exerted by the motor, which is amplified by the closed kinematic chain.  
According to the main design goals stated before, the design of the mechanism must be optimized to 
accomplish a minimization of the motor size, as well as of the overall size of the device. The design 
procedure has involved the definition of the length of the links, of the joint positions and of the spring 
parameters. The goal of the optimization is the minimization of the maximum torque that the motor 
should provide to open the mechanism. The motor torque, which depends on the value of the 
independent coordinate q, is evaluated within the usable workspace Q, which is defined as the range 
of the angular rotation of the driving link 1 between the open and the closed configurations. 
The achievement of a feasible design as the result of a numerical optimization technique is ensured 
by defining some constraints. The first constraint is set on the displacement of the pinching element: 
it must be ensured that the overall displacement of point C is adequate to produce a displacement that 
is at least equal to the inner diameter of the tube, i.e. 2.6 mm. Additionally, the force exerted on the 
tube, denoted 𝑓𝐶𝐿𝐴𝑀𝑃 in Figure 46, must be higher than 50 N. These two constraints require a careful 
trade-off: a larger displacement of point C is achieved by reducing the ratio between the lengths z3 
and z6, as well as the ratio between z8 and z6, as well as with the increase of the length z11. However, 
these changes in turn have the negative effect of reducing the force advantage. 
The equilibrium equations for the mechanism can be inferred through the principle of virtual works 
in all the pinching configurations. When the motor is switched off, the sole external forces acting on 
the mechanism are the spring pull 𝒇𝐸𝐿and the clamping force 𝒇𝐶𝐿𝐴𝑀𝑃. The resulting static equilibrium 
is therefore: 
 
 
[𝑓𝐸𝐿
𝑥 𝑓𝐸𝐿
𝑦 ]
[
 
 
 
 
𝜕𝑥𝑀
𝜕𝑞
𝜕𝑦𝑀
𝜕𝑞 ]
 
 
 
 
+ [𝑓𝐶𝐿𝐴𝑀𝑃
𝑥 𝑓𝐶𝐿𝐴𝑀𝑃
𝑦 ]
[
 
 
 
 
𝜕𝑥𝐶
𝜕𝑞
𝜕𝑦𝐶
𝜕𝑞 ]
 
 
 
 
= 0 (1) 
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Equation (1) includes the sensitivity coefficients of the cartesian positions of points C and H, which 
can be evaluated as: 
  
 𝜕𝑥𝐶
𝜕𝑞
= 𝑧11 sin(𝜑11)
𝜕𝜑8
𝜕𝑞
 (2) 
 
 𝜕𝑦𝐶
𝜕𝑞
= −𝑧11 𝑐𝑜𝑠(𝜑11)
𝜕𝜑8
𝜕𝑞
 (3) 
 
 𝜕𝑥𝑀
𝜕𝑞
= −𝑧10 𝑠𝑖𝑛(𝜑8)
𝜕𝜑8
𝜕𝑞
 (4) 
 
 𝜕𝑦𝑀
𝜕𝑞
= 𝑧10 𝑐𝑜𝑠(𝜑8)
𝜕𝜑8
𝜕𝑞
 (5) 
 
 
In Equations (2-5), and throughout the whole section, the angles φi (i=1,…,12) denote the absolute 
angular position of vectors zi. The computation of Equations (2-5) requires evaluating the following 
sensitivity coefficient: 
 
 𝜕𝜑8
𝜕𝑞
=
𝑧1𝑧6
𝑧3𝑧8
sin(𝑞 − 𝜑2)
sin (𝜑2 − 𝜑3)
sin(𝜑6 − 𝜑7)
sin (𝜑7 − 𝜑8)
 (6) 
 
Equation (1) will be included in the optimization routine to ensure a sufficiently large occlusion force, 
thus allowing for the achievement of a proper spring design.  
The actuator effort in the open configuration is evaluated by including the effects of the torque 
generated by the motor, Tm, and the spring pull. The small force due to the interaction with the tube 
in this phase is reasonably neglected. The resulting static equilibrium equation is: 
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[𝑓𝐸𝐿
𝑥 𝑓
𝐸𝐿
𝑦 ]
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𝜕𝑥𝑀
𝜕𝑞
𝜕𝑦
𝑀
𝜕𝑞 ]
 
 
 
+ 𝑇𝑚 = 0 
(7) 
 
Although all the design parameters of the mechanism have a strong influence on its performances, 
the large number of variables suggests including just a subset of them within the optimization 
parameters vector. Indeed, the effectiveness and the convergence of a nonlinear constrained 
optimization routine is easily jeopardized by large scale problems [50]. Therefore, the number of 
optimization parameters has been kept to a minimum by performing a preliminary design of the 
mechanism, which has involved the choice of the lengths of the links of the two cascaded four-bar 
mechanisms. Such a preliminary design has been carried out considering that the mechanical 
advantage is directly proportional, among the others, to the ratios of the link lengths 𝑧3/𝑧1, 𝑧6/𝑧8 as 
shown in Eq. (6), as well as the ratio 𝑧8/𝑧11, which appear in the sensitivity coefficients of Equations 
(2-5). These ratios have therefore been set to be as high as possible, considering also the trade-off 
between getting high force magnification and assuring an adequate displacement at point C, and while 
avoiding interference or collisions. 
The effects of the other geometrical parameters included in the design have a less straightforward 
interpretation and therefore their optimal values will be computed through the numerical 
optimization. The numerical optimization routine therefore includes the following design parameter 
vector: 
 
 𝒙 = [𝑥𝑁 , 𝑦𝑁 , 𝐿0, 𝑧10, 𝛾36] (8) 
 
Parameters 𝑧10, 𝐿0, 𝑥𝑁 and 𝑦𝑁 set the features of the spring-loading mechanism to be optimized, 
being 𝐿0 the free length of the spring. Moreover, the constant angle between vectors 𝒛3 and 𝒛6, 
denoted 𝛾36, is to be determined through the optimization routine as well. This parameter has a strong 
influence on the performance of the mechanism, since it affects both the absolute value of the 
sensitivity coefficient 𝜕𝜑8/𝜕𝑞 and the overall displacement of the contact point 𝐶, as shown in Figure 
48 and Figure 49. 
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Figure 48. Sensitivity coefficient  𝜕𝜑8/𝜕𝑞   vs 𝑞 with different choices of 𝛾36 in the ±𝜋/6  range 
 
Figure 48 shows how 𝜕𝜑8/𝜕𝑞 is affected by 𝛾36 in the range ±𝜋/6 rad. Results are reported for the 
usable workspace 𝑄, which is defined as the subset of the whole workspace for which 𝜕𝜑8/𝜕𝑞 is 
adequately far from singularity to assure back-drivability, and that the torque needed to counteract 
the spring pull always takes positive values. Such a threshold has been chosen equal to 0.04. Figure 
48 reveals that larger values of 𝛾36 lead to higher force magnification.  
Figure 49 shows the total displacement of the contact point 𝐶 against 𝛾36. The results reveal that 
larger values of 𝛾36 reduce the amplitude of the displacement of the pinching element, up to the point 
that the displacement of point 𝐶 is too small to produce a full tube occlusion. The most suitable value 
of 𝛾36 must therefore result from a careful trade-off between these two opposite effects. Such a feature 
will be ensured through the solution of the optimization routine. 
 
Figure 49.  Maximum displacement of point 𝐶 vs. 𝛾36 
 
The stiffness of the spring has been chosen by evaluating the trade-off between the overall size and 
the needed stiffness, considering that the latter should provide adequately large forces with small 
displacements. 
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The resulting optimization procedure produces an optimal choice of the five parameters included in 
vector 𝒙 that minimizes the scalar cost function 𝐽 defined as follows: 
 
 𝐽 = min
𝑞∈𝑄
max𝑇𝑚(𝑞, 𝒙) (9) 
 
The cost function 𝐽 of Eq. (9) is chosen to minimize the peak value of the torque that the motor must 
exert to counteract the spring pull throughout the whole usable workspace. Such a motor torque can 
be computed according to the equilibrium of Eq. (7). The choice of a “minmax” cost function is 
chosen to minimize the size of the motor, given the peculiar use of the clamp which consists in 
keeping the clamp open, i.e. with negligible exerted torque, for most of the time. Hence, the most 
critical motor parameter is the maximum torque. 
The need for a feasible optimal design requires to include into the optimization routine some 
constraints, that result in nonlinear constraints: 
 
 𝑓𝐶𝐿𝐴𝑀𝑃 ≥ 50 
 
Δ𝐶 ≥ 2.6 
 
𝑦𝑁 ≤ −5 
(10a) 
 
(10b) 
 
(10c) 
 
The first constraint ensures that the clamping force is sufficient to produce a full occlusion of the 
tube, and is evaluated according to Equation (1). The constraint of Equation (10b) is set to ensure a 
sufficiently large displacement of point 𝐶 throughout the workspace 𝑄. Such a displacement is set to 
be at least equal to the inner diameter of the tube.  
The third constraint is chosen to ensure that there is no interference between the fixed end of the 
spring, located at point N, and the shaft of the motor. 
The design optimization has been performed by using a pattern search method based on the simplex 
algorithm. The outcome of the minimization procedure has been compared with the result of a genetic 
algorithm procedure [51], which has produced the same results, thus corroborating the convergence 
of the optimization. The parameters of the optimized design are shown in Table 15. The table lists 
also the position of the fixed revolute joints, the link lengths, the spring stiffness 𝑘 and the spring free 
length 𝐿0. 
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O = [0;0] mm D = [8.5; 0] mm H = [17;0] mm 
N = [-14;-5] mm 𝑧1= 4 mm 𝑧2= 12 mm 
𝑧3= 10 mm 𝑧6= 4 mm 𝑧7= 12 mm 
𝑧8= 10 mm 𝑧10= 8.5 mm 𝑧11= 5.3 mm 
𝛾36= 0.2187 rad 𝑘 = 3000 N/m 𝐿0= 16 mm 
Table 15. Optimal design parameters 
 
 
 
Figure 50.  Motor torque 𝑇𝑚 vs independent coordinate 𝑞 
 
The resulting motor torque is represented in Figure 50 for all the configurations within the usable 
workspace Q. The small peak torque needed to achieve the equilibrium allows for the use of a 
relatively small size motor with no gearboxes.  
The clamping force is shown in Figure 51. It also complies with the design specifications, since it is 
larger than 50 N for every configuration within the usable workspace Q. The clamp is completely 
closed for 𝑞 = 0.7429 rad, for which the force exerted on the tube is equal to 50 N. Such a 
configuration is equilibrated by a minimum value of the motor torque 𝑇𝑚, according to Figure 50, 
since link 1 and 2 are almost aligned. The fully open configuration corresponds to 𝑞 = 4.153 rad: in 
this configuration, the motor must produce a torque that is roughly equal to 0.015 Nm. Such a small 
value ensures a reduced power consumption in the normal operation of the device. 
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Figure 51.  Clamping force 𝑓𝐶𝐿𝐴𝑀𝑃  vs independent coordinate 𝑞 
 
The position analysis of the mechanism is sketched in Figure 52, which shows the configurations of 
the mechanism for ten equally spaced crank positions within the usable workspace 𝑄. The figure 
shows that link 1 and 2 are close to the alignment for both the open and the closed configuration. 
 
Figure 52.  Mechanism displacement throughout the workspace 𝑄 
 
The actual displacement of the clamping point for the optimized design is shown in Figure 53. Such 
a plot shows that the total displacement of the point C is equal to 2.6 mm, and is therefore adequately 
large to produce a full occlusion of the blood-carrying tube. This feature has been enforced by the 
nonlinear constraint of Equation (10b).  
Given the required, a pancake Sanyo Denki stepper motor has been chosen. Such a motor can provide 
a continuous holding torque equal to 83 mNm when operated using 24 V DC power supply. The 
choice of a stepper motor is motivated by the common unavailability of slim profile DC motors. The 
advantages of the reduced space occupation of a stepper motor comes at the cost of a less simple drive 
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circuit, that is required to provide the correct current at each phase of the motor. The motor can 
provide the needed torque to keep the clamp in the open position with a power consumption that is 
estimated to be nominally equal to 143 mW (i.e. without considering the power losses of the driving 
circuit and the efficiency loss due to the heating of the motor). This value satisfies the design 
specification of 1 W.  
In order to verify that the complete closure of the pipe is obtained within the required maximum time, 
the dynamic response of the mechanism is investigated through forward dynamic analysis. This 
analysis is needed to evaluate whether the system can avoid the injection of an air bubble into the 
patient’s circulating system by occluding the pipe in a sufficiently small amount of time. 
 
Figure 53.  Clamp displacement vs independent coordinate 𝑞.  
 
The system dynamics has been therefore modelled by accounting for the spring force, the inertial 
contribution of the motor shaft, and by representing the tube resistant force as a constant term 𝑓𝑡𝑢𝑏𝑒 =
25 N. Additionally, the detent torque 𝑇𝑑 (i.e. the torque required to rotate the motor shaft with no 
current applied to the windings) of the stepper motor has explicitly considered in the evaluation and 
estimated as 1/10 of the motor holding torque, as it often happens in commercial motors. Such a value 
has been also experimentally verified through direct measurements on a motor sample. Other sources 
of friction, such as the friction at the joints, are neglected. Indeed, it is reasonable assuming that 
friction at the joint can be kept small by introducing suitable joint clearance. Such a clearance does 
not affect significantly the motion of the mechanism, given the presence of spring preload. In order 
to consider a worst-case scenario, an overall constant inertia 𝐽𝑡𝑜𝑡 equal to twice the motor one has 
been considered (𝐽𝑡𝑜𝑡= 0.03·10
-4 kgm2). The approximated dynamic model during the spring-induced 
motion can therefore be written as: 
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𝐽𝑡𝑜𝑡?̈?(𝑡) = 𝑓𝐸𝐿
𝑥
𝜕𝑥𝑀
𝜕𝑞
+ 𝑓𝐸𝐿
𝑦 𝜕𝑦𝑀
𝜕𝑞
− 𝑇𝑑
− 𝑓𝑡𝑢𝑏𝑒
𝜕𝑥𝐶
𝜕𝑞
 
(11) 
 
 
Equation (11) has been integrated from the initial conditions 𝑞 = 4.153 rad and ?̇? = 0 rad/s. The 
solution of the forward dynamics highlights that the complete pipe obstruction, which happens when 
𝑞 = 0.7429 rad, is achieved after just 49 ms. Considering that the speed of blood along the tubes is 
roughly equal to 0.224 m/s and that the response time of the blood detector sensor is equal to 100 ms, 
air bubbles can only travel 33 mm after their detection. Therefore, to assure that air bubbles could be 
stopped even before reaching the clamp, a reasonable distance between the bubble detector and the 
clamp should be approximately 50 mm to include further safety margins. 
 
A prototype of the clamp presented and discussed above has been manufactured mainly by additive 
manufacturing technology. The prototype is shown in Figure 54. In the picture the clamp is shown 
occluding a single tube. The prototype has proved the expected good characteristics in terms of 
miniaturization and power consumption, also in comparison with commercially available clamping 
devices for medical use. However, a couple of relevant motivations have justified discontinuing the 
development of such a clamp mechanism and launching a new project (carried out in parallel with 
the doctoral one) for investigating the possibility of adopting a completely different approach to 
clamp design. Such a project has delivered a successful device, which is not discussed here for 
patentability reasons. The motivations which have suggested suspending the development of the 
clamp presented in this section are:  
1. the final selection of a volumetric and occlusive peristaltic pump for blood circulation has 
determined a reduction in terms of required clamping force: only a single tube needs to be 
occluded rather than two.  
2. the 3D printing manufacturing technology, which was the sole initially available, has shown 
some considerable drawbacks in terms of dimensional accuracy and robustness of the 
miniaturized links of the multibody.  
Admittedly, the design presented is still relevant because immediately employable in case a not 
occlusive pump was employed in a future development of the WUF. As for the limits of the 3D 
printing technology, they can all be overcome by just manufacturing the mechanism links using the 
more traditional subtractive technology. 
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The clamp design proposed in this section has also been published in the proceedings of the 
International Conference of IFTOMM Italy in Vicenza [52], and then selected for publication in the 
International Journal of Mechanics and Control. 
 
 
Figure 54. Prototype of an electromechanical clamp suitable to the WUF. 
 
 
5.3.5 Ultrafiltrate collection and volume measurement system 
The standard IEC60601-2-16, although it refers to chronic hemodialysis treatments, defines specific 
requirements on the control of hourly amount of ultrafiltrate to remove. It states that:  
a) the net fluid removal (decrease in time) must be within ±0.1 l/h with respect to the set point based 
on clinical prescription; 
b) the target net fluid removal is to be kept within ± 400 ml at any time during the treatment. 
 
It is therefore necessary to have a feedback control of the amount of ultrafiltrate removed from the 
patient, in order to avoid either excessive or reduced water extraction during the therapy. Such 
measurements are needed by the control system to regulate the ultrafiltration pump and keep the 
ultrafiltration flow as constant as possible throughout the therapy. Standard ultrafiltration machines 
collect ultrafiltrate into bags whose weight is measured by load cells (gravimetric method). However, 
this approach could be unreliable in a wearable device, since the measurement can be affected by 
changes in bag orientation end by the continuous oscillations induced by patient’s gait. To overcome 
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this problem, miniaturized flowmeters may be employed, since they allow keeping size and weight 
to a minimum, but in general they are extremely expensive.  
An effort towards designing disposable devices for measuring the ultrafiltrate volume is being made 
by a few companies.  
In this project, a completely novel approach combining level and acceleration sensors directly 
integrated in a suitable ultrafiltration tank has been developed. However, since this system is being 
patented, no further details can be provided in this paragraph.  
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5.4 Battery pack 
 
After having defined all the hardware components of the device, the overall power consumption has 
been estimated to select an appropriate battery as power source (Table 16).  
 
Components Estimated power consumption (W) 
Ultrafiltration pump 0.2 
Pressure sensors and electrical circuits 1 - 2.5 
Blood pump 7.2 
Safety Clamp 2 - 4 
2 Arduino microcontrollers 0.5 
1 Raspberry microcomputer 1 - 2.5 
Other components (e.g. display, heparin 
infusion system) 
< 1 
TOTAL  12.4 - 17.9 
Table 16. Summary of estimated power consumptions of the main components of the WUF 
 
In the worst case, the total power consumption is estimated about 18 W.  
In order to simplify battery management, it has been decided to use a power bank device that can be 
easily, effectively, and quickly recharged without stopping the therapy. The selected power bank 
battery is Powerbank XTPower XT-20000QC2. 
The characteristics and technical data of such device are summarized in Table 17. 
 
Battery type Lithium-Ionen 
Capacity 20400mAh (3,7V) / 75,5Wh 
Connections 
1x USB Standard Output 
1x USB Q2 Output 
1x DC Socket (OUTPUT/INPUT) 
1x Micro-USB socket (INPUT) 
Input 
1 x USB 5V 2.1A max. 
1 x DC Socket 13-20V 3A max. / 30W max. 
Output 
1 x USB 5V 2.1A 
1 x USB QC2 5V/2.1A 9V/2A 12V/2A 
DC Socket 
12V/16.5V/19V/20V/24V  
50 Watt continuous / 65 Watt max. 
Dimensions 174 x 78 x 21.5 mm 
Weight 450g 
Table 17. Technical data of the power bank unit selected for the WUF 
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The full charge stored in the battery, can assure a duration of battery-operated therapy ranging 
between 4 (worst case) and 6 (best case). For patients, such a battery life is far enough to guarantee 
performing many daily activities, such as commuting, leisure and playful activities (e.g. walking 
outdoors), or long-distance travels. In the last case the possibility of recharging the battery by just 
plugging into a standard electrical outlet greatly simplifies the WUF operations and extends its range 
of use. 
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6. Control Architecture 
 
The control architecture applied for the WUF prototype is shown in Figure 55. The architecture has 
been carefully designed to meet both the restrictive requirements imposed by the application (the 
development of a miniaturized, energy efficient and wearable device which could be monitored 
remotely) and those imposed by the directives and by the need to minimize risk for patients. As shown 
in Figure 55, the architecture includes two main sections that have been named “program application 
section” and “device control section”. The selected microcomputer and the two microcontrollers can 
successfully implement such an architecture.  
 
 
Figure 55. WUF control architecture 
 
The main tasks of the program application section are: 
• to set up the device on the basis of the treatment parameters,  
• to manage network communication,  
• to collect and sort therapy data,  
• to show the clinical treatment information using a GUI during the whole treatment, 
supporting remote monitoring.  
The microcomputer Raspberry PI 3 model B can perform all these tasks. Based on the peculiar field 
of application of the WUF, it has been chosen to make it possible to check therapy data and download 
reports and charts, in three ways:  
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• by opening a specific web page on the web server installed in the microcomputer through a 
generic internet-like connection; 
• by visualizing the GUI running on the microcomputer from a remote terminal through VNC 
connection; 
•  by using HL7 transmission protocol, to exchange data with the hospital information system.  
HL7 (Health Level 7, standard ISO 16527) is a specific standard protocol for exchanging information 
between medical applications. This standard defines a format for the transmission of health-related 
information.  
The device control section, instead, receives the reference commands from the GUI (and hence from 
the program application section) or from the touchscreen monitor, reads the feedback signals from 
the transducers, and basically suitably drives the actuators of the pumps to perform the therapy. It 
also returns information on the status of the system (pressure values, amount of UF removed, etc.) to 
the GUI via USB connection. The two miniaturized microcontrollers (Arduino Mega) can manage 
this process in real-time: a dual parallel safety-loop has been designed in order to implement 
redundancy control. The two microcontrollers must read the signals measured by the transducers and 
detect potential non-compliant situations.  
More in details, the control system implemented in one of the two Arduino Mega completely manages 
the ultrafiltration therapy. The control system reads signals from the sensors and provide the correct 
set point to the pumps. Data are transmitted at pre-set intervals to the microcomputer that stores them 
in a data log file, allowing a complete monitoring of the therapy. 
In the second Arduino Mega (the “protective” one), the protection system has been implemented: 
such a microcontroller reads the signals from the sensors. 
The firmware with which the two microcontrollers have been programmed has the task of cyclically 
scanning the ports to which the devices are connected, processing data and saving them into a special 
60 Byte array. In case of out of range measures or mismatches between the measures read by the 2 
microcontrollers, the safety procedure, requiring the treatment interruption by stopping the pumps 
and the closure of the safety electro-mechanical clamp, is activated. At the same time, one bit of the 
communication array is set at a high logical level in order to immediately communicate the current 
status and to display the alarm information on the GUI. Furthermore, the protective microcontroller 
is connected with the LCD touchscreen through which the patient can immediately understand the 
status of the therapy as well. The safety procedure can be activated even manually through an 
emergency stop button and any alarm or warning detected by the system is signaled through a buzzer. 
In order to further improve the overall system safety, a watchdog hardware component has been 
applied to check the microcomputer status continuously.  
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As for the programming languages chosen for the GUI, they are C++ and Python because of their 
versatility and software portability. With reference to the web environment, PHP, HTML and MySQL 
have been selected for the onboard web server: they allow encryption of patients' data and the possible 
scheduling of backup copies of all the device data, which are also downloadable through remote 
terminal via FTP server.  
As for the programming languages chosen for the GUI, they are C++ and Python because of their 
versatility and software portability. With reference to the web environment, PHP, HTML and MySQL 
have been selected for the onboard web server: they allow encryption of patients' data and the possible 
scheduling of backup copies of all the device data, which are also downloadable through remote 
terminal via FTP server. 
 
The control architecture proposed in this section, together with a general conceptual design of the 
WUF, has also been published in the proceedings of the International Conference of IFTOMM Italy 
in Vicenza [53]. 
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7. Control logic 
 
An accurate definition of the control logic has been carried out for the overall ultrafiltration therapy 
to be performed with the WUF. As previously explained the two microcontrollers and the 
microcomputer perform different tasks. In particular, the safe control of the device pumps and 
actuators is carried out by the two Arduino Mega microcontrollers which must also acquire and 
process sensor signals as well as detect and manage possible hazardous situations. The control logic 
has been developed based on clinical requirements, risk analysis, and after investigating thoroughly 
the behavior and the performances of some standard and reliable extracorporeal blood ultrafiltration 
machines in hospital.  
The control logic has been structured in three main operational phases to be performed with the WUF. 
They are:  
• Setup phase; 
• Therapy phase; 
• Termination phase. 
All these phases have been translated into software programs running on the microcontrollers and the 
microcomputer. Each phase has been further divided into relevant clinical procedures, reflecting 
requirements arisen from the risk analysis, and technical steps to be executed. The GUI has been 
developed in order to allow hospital staff to manage and monitor the state and progression of the 
therapy from the beginning to the end.    
The scheme describing the main control logic is represented in Figure 56. 
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Figure 56. The main scheme describing the control logic of the WUF 
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7.1 Setup phase 
The setup phase consists of the following clinical procedures: 
• Switching on of the device; 
• Mounting of the disposable components on the non-disposable panel; 
• Priming of the extracorporeal circuit; 
• Prescription of the therapy;  
• Connection to the patient. 
The switching on of the device is the first step of the setup phase. During this state, the system verifies 
the communication between the two microcontrollers and the microcomputer. If the communication 
test is passed and the user authorizes the start the therapy by the GUI (Figure 57), the system enters 
the mounting procedure. 
 
 
Figure 57. Main screen of GUI after the switching on of the device 
The mounting procedure consists in preparing the device with all its physical components. Such a 
procedure needs to be performed in hospital by a trained nurse. The peculiar design of the WUF 
drastically simplifies such a procedure, since, as it will be described in the next chapter, all single use 
components are grouped in a single panel which can easily hooked to and unhooked from the non-
disposable panel of the WUF, which is fixed to a rigid frame. During the mounting procedure all the 
pumps are stopped and the clamp is kept open to allow the mounting of the tubes. The possibility to 
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proceed to the next step (priming procedure) is assured by either the GUI of the microcomputer or a 
button displayed in the touchscreen monitor. 
The priming is the most important procedure to be performed in the setup up phase. The priming is 
performed in order to fill the extracorporeal circuit with physiologic solution, remove all the air from 
the circuit, deposit some heparin along the inner surfaces of the hemofilter and tubes, and check if 
the circuit and the sensor have been well connected. 
In particular, the technical steps performed during the priming procedure are: 
1. To command the clamp to an open state configuration. 
2. To set the velocity of the blood pump at 50 ml/min, with the UF pump switched off, for a 
duration of 4 minutes. After 2 minutes from the starting of this step, the heparin pump is set 
at 2 ml/h (33 µl/min). This step allows the prefilling of the blood compartment of the 
extracorporeal circuit and of the hemofilter.  
3. To verify the correct connection of the disposable pressure sensors. This step is considered 
passed if at least 3 consecutive measures of each pressure sensor are collected and are non-
zero. 
4. To verify if the blood flow rate (50 ml/min) is correct. In order to do this, pressure 
measurements are collected to estimate the blood pump velocity. More details on such an 
estimation process are provided below, since it is used in the treatment routine too.  
5. To fill the ultrafiltration compartment. In order to do this, the electro-mechanical clamp is 
closed and the blood pump is set at 50 ml/min until the ultrafiltrate tank starts to detect 
water.    
6. To open the electro-mechanical clamp, to set the blood pump at 50 ml/min and the 
ultrafiltration pump at 7 ml/min. The duration of this step is 1 minute. At the same time, 
pressure measurements from all the sensors are collected. This step is performed in order to 
start to fill the arrays of pressures measurements necessary to be applied in the next step.  
7. To close the electro-mechanical clamp, to stop the pumps (both the blood and UF ones) and 
to close a manual clamp placed in the ultrafiltration circuit. This operation can be performed 
by the touchscreen monitor.  
8. To confirm by the touchscreen monitor that the clamp in the UF line has been manually 
closed by pressing the corresponding button.  
9. To carry out the pressurization test in order to verify that there are no leakages in the 
extracorporeal circuit. The blood pump is set at 50 ml/min with the electro-mechanical 
clamp in the blood line and the manual clamp in the ultrafiltrate line that are closed. Sensor 
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signals, whose sample rate is at a frequency of 20 Hz, as it will be explained later, are low-
pass filtered by a 16-tap moving average (see APPENDIX B). As soon as one among the 
pre-filter pressure, return pressure or ultrafiltrate pressure reaches the value of 300 mmHg, 
the blood pump is stopped. After 2 seconds, the three moving average pressure values are 
compared: if the difference between these is less than 40 mmHg for at least 5 seconds, the 
test is passed.  If none of these pressures reaches the value of 300 mmHg in a period longer 
than 10 seconds from the start of the test, or if the comparison between at least two of the 
three moving average pressure measures is higher than 40 mmHg for the first 5 seconds, an 
alarm on the touchscreen monitor appears and the pressurization test needs to be repeated. 
10. To open the electromechanical clamp, to set up the blood flow, the UF flow and the heparin 
flow at 50 ml/min, 7 ml/min and 2 ml/h respectively. This step is performed for 3 minutes. 
11. To perform the self-test of the air bubble detector, to calibrate and perform the self-test of 
the BLD sensor, to check the temperature sensor.  
12. To check the status of the microcomputer by the watchdog in the protective microcontroller.
            
Part of the priming procedure represented in the GUI is shown in Figure 58. 
 
 
Figure 58. Sample screen of part of the priming procedure in the GUI 
It is necessary to stress that, during some steps, a continuous check on pressures inside the circuit is 
performed. In particular, the moving average low-pass filter is applied to access pressure, pre-filter 
pressure and return pressure in the above steps 2, 4, 6 and 10. The allowable range of access pressure 
has been set between -300 mmHg and +50 mmHg. The allowable range of pre-filter pressure and 
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return pressure has been set between -50 mmHg and +300 mmHg. The moving average low-pass 
filter is applied to UF pressure in steps 6 and 10. The allowable range of UF pressure has been set 
between -300 mmHg and +300 mmHg.   
The next procedure is related the accurate therapy prescription. The parameters to be set are: 
• The blood flow rate; 
• The ultrafiltration flow rate and the target ultrafiltrate volume to be removed during the overall 
treatment session; alternatively, it is possible to set the ultrafiltration flow rate and the treatment 
duration, or the target ultrafiltrate volume to be removed during the overall treatment session 
and the treatment duration; 
• The heparin flow rate (it can be disabled) or the volume of heparin bolus and periods of 
infusion. 
Finally, the connection procedure is carried out by connecting the access line and return line directly 
to the catheter of the patient. 
Before entering the therapy phase, it is necessary to confirm the choice manually by both the GUI 
and the touchscreen.  
 
7.2 Therapy phase 
The second operational phase is the one corresponding to the ultrafiltration therapy.  
The first procedure to be performed is blood circulation. Indeed, before starting with the 
ultrafiltration, it is important to fill the extracorporeal circuit with the patient’s blood without 
removing water. This procedure is performed for 3 minutes.  
After the blood circulation procedure, the ultrafiltration treatment starts. The main page of the therapy 
phase visualized in the screen is shown in Figure 59. 
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Figure 59. Sample screen during the therapy phase in the GUI 
The main loop of the therapy phase manages the following operations: 
• To command blood pump, ultrafiltration pump and heparin pump based on clinical 
prescription; 
• To read and manage all the signals coming from the sensors. The management of the sensor 
implies, for example, the periodic launch of the self-test (air bubble detector sensor and 
BLD) and of the test for correct reading (pressure sensors). In particular, the sensors are: 
o Pressure sensors; 
o Air bubble detector sensor; 
o BLD sensor; 
o Temperature sensor; 
o Sensors for measuring the ultrafiltrate volume; 
o Sensors for measuring if the heparin tank is empty; 
• To command the electro-mechanical clamp if a hazardous situation is detected; 
• To manage and to verify the communication between the microcontrollers and the 
microcomputers; 
If a hazardous situation is detected, the device automatically enters the state of alarm. In this state, 
the device automatically reacts by stopping the pumps and occluding the clamp based on the type of 
alarm and its risk. The alarm can be reset: if the problem is solved, the therapy can be carried on, 
otherwise the system re-enters the state of alarm. Table 18 shows the list of alarms detectable with 
the WUF and expedients that the device carries out in order to avoid any harm to the patient.    
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Alarm Actions to be adopted 
Access pressure error (difference in the signals acquired by the two 
microcontrollers) 
To stop all the pumps and to close the clamp 
Access pressure lock (Access pressure is not measured correctly) To stop all the pumps and to close the clamp 
Access pressure below lower limit To stop all the pumps and to close the clamp 
Access pressure above upper limit To stop all the pumps and to close the clamp 
Air detection To stop all the pumps and to close the clamp 
Air detection test error (self-test not passed) To stop all the pumps and to close the clamp 
Anomaly on the clamp power supply circuit To stop all the pumps and to close the clamp 
BLD installation error (self-test not passed) To stop all the pumps and to close the clamp 
Blood Leak Detector error (difference in the signals acquired by the 
two microcontrollers) 
To stop all the pumps and to close the clamp 
Blood leakage To stop all the pumps and to close the clamp 
Blood pump not stopped when it should be To stop all the pumps and to close the clamp 
Blood pump speed error To stop all the pumps and to close the clamp 
Blood pump stopped when it should not be Warning in the screen appears 
Clamp is not closed when it should be To stop all the pumps  
Clamp is not opened when it should be To stop all the pumps and to close the clamp 
Excessive Volume variance (the difference between expected Volume 
loss and real Volume loss is too high) 
To stop the ultrafiltrate pump 
Heparin reservoir is empty To stop all the pumps and to close the clamp 
Low battery voltage To stop all the pumps and to close the clamp 
Microcomputer error To stop all the pumps and to close the clamp 
Microcontroller 1 (controller system) error To stop all the pumps and to close the clamp 
Microcontroller 2 (protective system) error To stop all the pumps and to close the clamp 
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Parameters out of range  
Pre-filter pressure error (difference in the signals acquired by the two 
microcontrollers) 
To stop all the pumps and to close the clamp 
Pre-filter pressure lock (Pre-filter pressure is not measured correctly) To stop all the pumps and to close the clamp 
Pre-filter pressure below lower limit To stop all the pumps and to close the clamp 
Return pressure error (difference in the signals acquired by the two 
microcontrollers) 
To stop all the pumps and to close the clamp 
Return pressure lock (Return pressure is not measured correctly) To stop all the pumps and to close the clamp 
Return pressure below lower limit To stop all the pumps and to close the clamp 
Temperature below lower limit To stop all the pumps and to close the clamp 
Temperature above intermediate limit  To switch on a cooling fan 
Temperature above upper limit  To stop all the pumps and to close the clamp 
Temperature error (difference in the signals acquired by the two 
microcontrollers) 
To stop all the pumps and to close the clamp 
TMP above upper limit To stop all the pumps and to close the clamp 
UF pressure lock (UF pressure is not measured correctly) To stop all the pumps and to close the clamp 
UF pressure below lower limit To stop all the pumps and to close the clamp 
UF tank full To stop the ultrafiltrate pump 
Ultrafiltrate pressure error (difference in the signals acquired by the 
two microcontrollers) 
To stop all the pumps and to close the clamp 
User interface error To stop all the pumps and to close the clamp 
Volume of removed ultrafiltrate error (difference in the signals 
acquired by the two microcontrollers) 
To stop all the pumps and to close the clamp 
Volume of removed ultrafiltrate has exceeded the safety limit To stop the ultrafiltrate pump 
Table 18. List of alarms detectable by the WUF 
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In particular, the following alarms: 
• Blood pump not stopped when it should be 
• Blood pump speed error 
• Blood pump stopped when it should not be 
needed a specific investigation to understand how to detect the actual blood pump speed (and 
consequently the blood flow) not using any specific sensor for a direct measurement. As stated before, 
the blood flow can be estimated by variations of pressure inside the circuit and measured starting 
from the velocity of the blood pump.  
During the therapy phase, another state can be selected: the pause one. In this temporary state, the 
pumps are switched off. By pressing a button on the touch screen monitor or directly by the GUI, it 
is possible to resume the therapy.   
Another important procedure is the one to empty the ultrafiltrate tank. This procedure can be set 
directly from the therapy page in the GUI (or in the touchscreen monitor) by pressing the specific key 
“CHANGE BAG” (Figure 60). 
 
Figure 60. Key for the procedure of ultrafiltrate bag change/ tank emptying in the GUI 
In this state, the UF pump is stopped, while the other pumps (blood and heparin) and all the sensors 
in the blood extracorporeal circuit continue to work normally. Once the procedure has been 
completed, the therapy can be carried on. 
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7.3 Termination phase 
When the therapy is finished, the user can press in the GUI the key “End therapy” (see on the bottom-
right corner of Figure 60): all pumps are stopped and the termination phase starts. It is important to 
remark that this phase must be performed in the hospital with a trained nurse that has to perform all 
the needed operations, in the proper order, which is listed and guided by the GUI.  
The first procedure of the termination phase is blood reinfusion into the patient. To do this, the access 
line needs to be disconnected from the catheter and connected to a physiological solution (Figure 61).  
 
Figure 61. Blood reinfusion procedure represented in the GUI 
During the blood reinfusion procedure, the device activates the blood pump at 50 ml/min for 30 
seconds (the priming volume of the extracorporeal circuit is almost 20 ml), while all the measures 
coming from sensors are continuously checked. Additionally, there is the possibility to re-infuse more 
volume by pressing a specific key in the GUI (“Manual reinfusion adjustment”). 
After having reinfused the blood to the patient, the blood pump is stopped and the return tube can be 
disconnected from the catheter. The device enters the dismounting procedure. After opening the 
electro-mechanical clamp, it is possible to easily remove the panel disposable components from the 
non-disposable one.  
Finally, the device can be switched off.   
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8. Design of the device 
 
 
The WUF layout has to be designed meeting the following specific requirements: 
• Satisfactory ergonomics when worn 
• Low weight and compact dimensions 
• Ease of movement for the patient during daily activities 
• Comfort for the patient even when sitting or lying (possibly providing the possibility of 
continuing the therapy without wearing the device) 
• Easiness in assembly and dismounting disposable components 
• Easiness in reaching not disposable component for maintenance 
• Stability of the device when not worn (for temporary or continuous needs) 
 
Based on these considerations and analysis of previous proposals from the literature, three main 
layout proposals have been taken into account. They are (see Figure 62 for example of the first two 
layout proposals): 
• Belt-like device (horizontal arrangement); 
• Jacket device (frontal arrangement);  
• Backpack device (rear and vertical arrangement). 
 
 
Figure 62. Layout proposal for the WUF: belt-like and jacket. 
 
As for the belt-like device, if on the one hand it allows an immediate visual evaluation of any 
problems during the treatment, on the other it limits the possibility of movement for the patient, 
reducing the number of daily activities that may be carried out comfortably. Moreover, such a layout 
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result scarcely convenient to use when not worn (for example, because the patient is lying in bed or 
sitting in an office). 
Similar considerations can also be applied for a jacket or a gilet layout: although the predominant 
vertical positioning of the components ensures an ordered and clear arrangement, the encumbrance 
for the patient is high and the usability of the device certainly limited. 
It is also important to point out that both the above-mentioned solutions may cause embarrassment in 
presence of other people, being extremely apparent. Additionally, the necessary replacement of 
disposable components at the beginning of the therapy may be made difficult by the disperse 
component arrangement, resulting in long setup preparations for healthcare nurses. 
Generally speaking, the WUF layout has to be designed with the aim of optimizing component 
positioning while keeping the device overall size to a minimum in terms of width, height and depth. 
For example, the peristaltic pump selected for blood circulation is characterized by a significant 
depth. In order to simplify the fitting of tubes in the pump rotor, it is certainly better arranging the 
pump orthogonal to the plane in which the other hydraulic components are positioned. This suggests 
abandoning a fully planar layout (such as those characterizing a sling or a belt), and preferring spatial 
arrangements exploiting all the volume in the three dimensions (i.e. a box-like displacements). In 
particular, in order to overcome the limits of the layout proposals previously described and in 
accordance with the requirements defined above, an innovative solution has been conceived for the 
layout of the WUF: a backpack/trolley design combined with a multi-layer displacement of 
components effectively collected into separate panels in accordance with their use and features. 
Figure 63 represents an initial conceptual idea of the WUF and clarifies such a concept of a 
multilayers approach in box-like design. 
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Figure 63. Conceptual layout introducing a box-like multi-layer design 
 
The box-like design fits well a backpack or a trolley, both guaranteeing good ergonomics and high 
levels of transportability of the device. In particular the chosen design allows: 
 
• to increase, thanks to the depth of the box, the available space for the arrangement of 
components;  
• to provide a good separation between disposable and non-disposable devices (by stacked 2D 
panels);  
• to ensure comfortable setup and disconnection operations;  
• to simplify the positioning of the battery pack and of the ultrafiltrate tank;  
• to extend usage opportunities: the trolley configuration can as comfortable as the backpack 
one and certainly preferable in case of lying patients; 
• to avoid embarrassment for patients, since the device can be well hidden during the treatment, 
inside an anonymous and compact backpack or trolley; 
• to simplify the measurement and the discharge of the extracted ultrafiltrate, thanks to the 
possibility to design a tank which can be kept almost vertical. 
 
It is clear that the adoption of a backpack imposes a high level of safety in case of alarm, since no 
immediate visual inspection is possible. However, the risk analysis previously carried out and the 
adopted safety measures can be considered enough to ensure safety even with such a layout.  
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The multi-layer layout proposed in this thesis has been translated into an arrangement of component 
into in three vertical parallel panels:  
• an internal and protected panel (the closest to patients’ shoulders) houses the electric and 
electronic components of the device including the three controllers,  
• an intermediate panel houses the non-disposable components (e.g. peristaltic pump, air sensor, 
blood leak detector), 
• an external panel houses all the disposable components of the device (and hence the entire 
circuit) and can be easily hooked to or unhooked from the intermediate respectively at the 
beginning or the end of the therapy.  
 
Through such a design there is the possibility to fully exploit the depth of the backpack (reasonably 
over 80 mm), and especially the space between the “electronic panel” and the “non-disposable” one, 
to include bulky components, as for example the peristaltic pump and the microcontrollers, without 
creating discomfort or limitations in the patient's movement. 
Figure 64 shows a 3D CAD view of the device, showing, in particular the non-disposable panel, the 
disposable one, the top cover of the device (housing the battery, a touchscreen monitor and a self-
locking red emergency stop push button), and the instrumented UF tank, which, again, smartly 
exploits the depth of the box-like design. The UF tank is big enough to collect two liters of 
ultrafiltrate, and therefore should not be emptied during the treatment. However, both for safety and 
comfort reasons, the tank it is equipped with a drain on the bottom. As for the box cover, it should be 
noticed that the touchscreen monitor can be placed in a movable case (not shown in the picture) which 
can be easily unlock from the cover and fastened to the backpack shoulder, hence becoming visible 
and usable along the whole therapy.  
The overall dimensions of the box are 405 x 300 x 140 mm and the estimated weight is less than 7 
kg: 5 kg of the device itself plus up to 2 kg of ultrafiltrate collected in the tank.  
Figure 64 also makes apparent that the multi-layer design drastically simplifies the change of the 
disposable components which are all collected on a single panel. Such a panel is the most external 
one and hence it is easily accessible when the backpack (see Figure 64) or the trolley are open. This 
allows keeping the duration of patients’ stays at the hospital to a minimum when a therapy is over 
and a new one is started. As a consequence, hospitalization costs are also kept to a minimum.  
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Figure 64. Final layout proposal for the WUF 
 
It is worth underling that in the design of both the non-disposable and the disposable panels, some 
constraints must be taken into consideration: 
• the 4 pressure sensors must be placed in specific positions in the extracorporeal circuit: 
o Access line 
o Pre-filter line 
o Return line 
o Ultrafiltrate line  
• the electro-mechanical clamp must be placed immediately before the blood returns to patient; 
• the heparin system must allow the heparin infusion before the blood enters into the hemofilter; 
• the ultrafiltration pump must allow filling the UF tank from the top.   
Figure 65 shows the CAD sketch of the “disposable panel” and the prototype of the panel 
manufactured using additive technology by an 3NTR A2v2 3D printer. In both the CAD sketch and 
the prototype picture, part of the heparin infusion system is masked since a verification of 
patentability is currently being made. 
The “non-disposable panel”, instead, has been equipped with components on both sides. In Figure 
66, the CAD sketch and the prototype of the frontal side are shown. In both the images, part of the 
heparin infusion system and the electro-mechanical clamp which has been developed in parallel with 
the one presented in Section 5.3.4 are masked for reasons of patentability. Louvers have been adopted 
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to guarantee natural and forced air circulation, especially in the areas where possibilities of 
overheating are higher (e.g. close to the blood pump and the electro-mechanical clamp). The panel is 
fixed to the main body (or in other words the frame) of the box by several screws on the perimeter. 
The connection between the “non-disposable panel” and the “disposable” one is obtained by several 
snap joints which simplify assembling and disassembling procedures.  
Figure 67 shows the CAD sketch of the reverse side of the “non-disposable panel”. The power board 
descripted in Section 5.2.4 is fixed just next to the motor of the blood pump. The motor of electro-
mechanical clamp is masked again for reasons of patentability. The PCB for the conditioning of the 
electric signals from pressure sensors and the one driving the UF pump have also been adapted on 
the back of this panel.  
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Figure 65. Disposable panel and components 
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Figure 66. Non-disposable panel and components 
125 
 
 
Figure 67. Reverse side of the “non-disposable panel” and components 
 
 
 
 
In Figure 68, the CAD sketch and the prototype of the assembling of disposable panel on the non-
disposable one are represented. 
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Figure 68. Mounting of the disposable panel on the non-disposable one 
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The inner part of the box contains the “electronics and controllers” layer. As shown in Figure 69, the 
main PCB, where the two microcontrollers have also been integrated, is approximately located in the 
center of the panel in order to minimize the electrical cabling. The microcomputer is positioned just 
below the main PCB, simplifying the USB cabling connection with the microcontrollers. On the right 
side of the panel, the driver of the clamp is visible. Furthermore, a cooling micro fan (not shown in 
the sketch) is mounted on the right wall of the box (opposite the UF tank) to generate forced 
ventilation in case the box internal temperature overcomes a set value. 
 
 
Figure 69. Inner part of the device containing the electronic layer  
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9. Conclusions 
The research activity presented and discussed in this thesis has led to the development of an 
innovative, safe, and easy-to-manufacture wearable and portable system for extracorporeal blood 
ultrafiltration named WUF. Such a device can potentially bring important social benefits by 
improving the quality of life in patients suffering from fluid overload condition while possibly 
reducing costs related to long hospitalizations. Additionally, it should ensure significant clinical 
advantages compared to standard current technology, thanks to a slow but continuous fluid removal 
allowing improved overall patient’s hemodynamic tolerance. 
The solutions adopted in the WUF have exploited the newest technological advances in fields such 
as sensors, micro pumps, actuators, membranes and related devices, microcontrollers, 
microcomputers and additive manufacturing technologies. The proposed mechatronic design has 
proved that several off-the-shelf components can be successfully employed, nonetheless novel 
approaches can still be developed to design some critical components as the electro-mechanical 
clamp.  
A considerable effort has been devoted to the design of an effective, efficient, safe and reliable control 
architecture. It has been proved that a couple of cheap and standard microcontrollers and a 
microcomputer allow meeting all these requirements. Then, an accurate definition of the control logic, 
based on clinical requirements and risk analysis, has been developed and structured in three main 
operational phases. These have been further divided into relevant clinical procedures, reflecting 
requirements arisen from the risk analysis and technical steps to be executed. In parallel, a user-
friendly graphical interface has been developed, in order to allow hospital staff to manage the status 
and progress of the therapy from the beginning to the end. 
An innovative layout paradigm has been introduced for the WUF, which involves: 
• a box-like design that can easily fit a backpack or a trolley: it guarantees the best tradeoff 
between miniaturization and ergonomics; 
• an original positioning of the vast majority of components on three independent planar panels: 
one for disposable devices, one for non-disposable components and one for electronic boards 
and controllers. Such an arrangement of components drastically simplifies and speeds up the 
in-hospital operations needed before and after a therapy with the WUF. 
A backpack design should be more suitable for younger patients who can easily wear the device 
during daily activities, while a trolley design should be more indicated for elderly patients who can 
perform the ultrafiltration therapy comfortably at home. Clearly, these reasonable hypotheses should 
be confirmed by extensive ergonomic investigations on (target) patients.     
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Both the commercial and the customized components of the WUF have been extensively tested and 
validated. The final commissioning of the prototype, manufactured with an extensive use of additive 
technology, allows confirming that the project for a wearable solution for ambulatory ultrafiltration 
in patients with fluid overload has been successfully completed from an engineering view point.  
In order to make the WUF compliant with the specific European Regulations, Directive and technical 
standards (mentioned in Chapter 4) regarding medical devices, the prototype needs first of all to be 
tested in vitro under medical supervision, in order to assess its safety, effectiveness and reliability. 
In particular, during the in vitro test, some possible open issues, that can be evaluated only by having 
the final complete prototype, can be addressed, including:  
• eventual electro-magnetic disturbances generated by the electric PCBs; 
• bugs in software integration and system testing; 
• device-related usability problems.    
This process, which requires a deep analysis and a long testing period (estimated in 6 months), is 
necessary to prepare an exhaustive documentation for the procedure of obtaining the CE mark by 
European Union. The in vitro testing phase will be performed in the Department of Nephrology of 
the San Bortolo Hospital. 
Since the WUF device does not introduce any new therapy for the treatment of fluid overload patients 
(ultrafiltration is a well-known clinical modality in this population and has been deeply studied in 
literature), no animal in vivo studies need to be performed before starting the clinical trial on humans.   
Consequently, after having obtained the CE mark, the subsequent step will be a phase-1 trial in 
humans after adequate regulatory license and Ethical Committee approval. 
Finally, a comparison between the main features of the available prototypes for renal replacement 
therapies and the WUF is proposed in the following Table 19. 
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  FEATURES 
 
 
Therapy 
efficiency 
Layout Weight 
Remote 
control 
Power 
consumption 
Software 
and control 
architecture 
Development and 
miniaturization of 
safety 
components 
D
E
V
IC
E
 
WUF    - -   
WAK   -    
ViWAK  -  * * - - 
AWAK  -  * * - - 
WHF      
RAD     *  - 
iNephron    - *   
WAKMAN  - -  *  * 
Table 19. Evaluation table referring to the main features of WUF and other prototype devices. Legend:  = very 
good,  = good, - = normal,  = bad,  = very bad, * = not enough available data. 
 
“Therapy efficiency” needs to be intended as the clinical effectiveness of the device of treating 
patients with fluid overload; “layout” is the spatial arrangements of all components (disposable and 
not disposable) which can facilitate the ordinary operativity of the device; “remote control” is the 
level of development of the software for the telemedicine; “software and control architecture” needs 
to be intended as effectiveness, efficiency, safety and reliability of software and microcontrollers; 
“Development and miniaturization of safety components” degree of innovation in developing 
mechatronic components of the device.         
Based on these results, the WUF has the best average mark with respect to other prototypes and is 
particularly innovative for what concerns layout and the development and miniaturization of safety 
components.  
Thus, the WUF can be considered as an extremely promising prototype in the field of wearable 
devices for extracorporeal blood ultrafiltration.     
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Appendix A 
In collaboration with researchers and clinicians of IRRIV and Department of Nephrology of San 
Bortolo hospital of Vicenza, a theoretical study has been carried out to select the minimum size, and 
in particular the lumen, of the catheter for the WUF. The lumen of a catheter is usually expressed in 
French, and it is most often abbreviated as Fr. The French size is three times the diameter in 
millimeters.  
From the hemodynamic point of view, it is necessary to take into account the Hagen-Poiseuille law: 
𝛥𝑃 =
(128 ∙ η ∙ Q ∙ L)
π ∙ 𝑑4
 
where ∆P is the pressure drop along the catheter, η is the blood viscosity, Q is the blood flow, L is 
the catheter length and d is the inner diameter of the catheter. 
Considering that blood viscosity does not vary so much (it depends on blood characteristics like 
hematocrit and protein concentration), the main parameters affecting pressure drop are the 
geometrical characteristics of the catheter (diameter and length). In particular, pressure drop is 
proportional to the fourth power of the diameter. Consequently, it would be desirable to increase the 
size of the diameter in order to reduce as much as possible the pressure drop and to avoid the catheter’s 
collapse as well.  
On the other hand, the catheter diameter cannot be excessively large, because it may fill the vein too 
tightly, possibly leading to a damage of vein wall, together with an increased risk of stenosis or 
thrombosis. A good compromise between these two aspects needs to be reached. 
In Figure 70 a Hagen Poiseuille law-based selection of the minimum diameter of a single lumen 
catheter for a wearable device is represented.  
In particular, the following assumptions were considered:  
- desirable blood flow of 50 ml/min, as defined by project requirements; 
- constant and standard length of the catheter for adults, L = 19cm; 
- patient venous pressure = 10 mmHg.  
The whole pressure drop between patient vessel and access pressure detecting point in the 
extracorporeal circuit is due almost entirely to the catheter.  
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Figure 70. Graph comparing the reachable blood flow and pressure drop inside the catheter. Color lines represent 
catheters with different sizes of the lumen. Green area represents the acceptable range between ∆P and catheter size for 
the desired blood flow. For 50 ml/min of blood flow, a 10 Fr is the minimum acceptable size of the lumen. 
In the access side of the catheter, which is more critical for the selection than the return one, the 
minimum pressure difference (∆P) along the length of the device should not exceed 350 mmHg [54] 
to avoid hemolysis and catheter collapse. However, this value does not take into account that blood 
flow is not uniformly laminar, the curvilinear deformation of the catheter after implantation and 
tubing roughness. For these reasons, a strict safety factor equal to 2 was taken into account to 
determine an acceptable value of pressure drop ∆P’: 
𝛥𝑃′ =
𝛥𝑃
2
= 175 𝑚𝑚𝐻𝑔 
Considering a dual D lumen catheter, in such conditions, a minimum size of 10 Fr (corresponding to 
an external diameter of 3.34 mm) catheter is required (Figure 71), matching technical requirements 
and clinical/ergonomics needs.  
 
Figure 71. Geometrical characteristics of the selected catheter 
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Appendix B 
The management of pressure signals coming from the sensors deserved an important and specific 
investigation. In order to do this, dedicated in vitro tests (Figure 72) have been carried out in hospital 
using blood. The aims of the test were: 
• to collect pressure values similar to in vivo ones;  
• to understand if a sample rate of 20 Hz (easily achievable by the Arduino microcontrollers) 
was adequate to detect immediately any obstruction; 
• to understand which was the best value to be retained in a moving average (easily 
implementable in the Arduino microcontrollers) to properly filter the signals.  
The miniaturized peristaltic pump selected for the WUF has been used. 
 
Figure 72. Setup of the in vitro experiment for testing the pressure sensors 
 
The peristaltic pump generates a periodic pressure signal caused by the so-called peristalsis 
phenomenon (it can be easily recognized in Figure 73). The period of the phenomenon clearly 
depends on the desired blood flow, and in the end, on the velocity of the pump. Since the chosen 
peristaltic pump has two rolls, each complete revolution of the pump rotor produces two peristalsis 
phenomena. In terms of blood flow, the target is between 50 and 70 ml/min which, based on the 
diameter of the rotor and of the pipe, is achieved by running the pump at about 42-60 rpm, but since 
there are 2 rolls, it means that the period of the peristaltic phenomenon is between 0.5 and 0.7 seconds 
corresponding to a frequency between 1.4 and 2 Hz. Based on these evaluations, a 20 Hz sample rate 
seems far enough to catch the phenomenon. 
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Figure 73. Typical signal patterns read by the sensors during the ultrafiltration therapy 
One the one hand it is appropriate to reduce the peristalsis phenomenon in the signals in order to 
minimize the risk to generate wrong alarms (apparent pressure peaks above the maximum limits), on 
the other the detection of the peristalsis phenomenon can be usefully exploited to measure the pump 
rotor velocity and to check whether the device is running properly. In order to meet both these 
requirements the sensor signals have been low-pass filtered by a 16-tap moving average filter, which 
introduces a cut-off frequency at about 0.5 Hz. As shown in Figure 74 by analyzing the filtered signal, 
the effect of an occlusion in the circuit can be detected in just 0.7 s, a period considered clinically 
appropriate. 
 
Figure 74. Original and filtered signals of pre-filter pressure sensor  
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